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Abstract 
 
Neuropeptide Y (NPY) is a neuromodulator in central nervous system (CNS) that can 
exert neuroprotective effects. NPY is expressed in mammalian retina but the location and 
potential modulatory effects of NPY receptor activation remains largely unknown. Retinal 
ganglion cell (RGC) death is a hallmark of several retinal degenerative diseases, particularly 
glaucoma. In purified RGCs, we detected immunoreactivity and mRNA for NPY and NPY 
receptors in these cells. Using cultured purified RGCs and ex vivo retinal preparations we have 
evaluated the effect of NPY receptor activation on changes in RGC intracellular free calcium 
concentration – [Ca2+]i and RGC spiking activity. RGC spike recordings were performed by a 
multi-electrode array (MEA). We found that NPY application attenuated the increase in the 
[Ca2+]i triggered by glutamate in purified RGCs, possibly via Y1 receptor activation. Moreover, 
Y1/Y5 receptor activation increased the initial burst response of OFF-type RGCs, though no 
effect was observed in the RGC spontaneous spiking activity. The Y1 receptor activation was 
able to modulate directly RGC responses by attenuating the N-Methyl-D-aspartic acid 
(NMDA)-induced increase in RGC spiking activity. These results suggest that Y1 receptor 
activation at the level of inner or outer plexiform layers leads to modulation of RGC receptive 
field properties. Using in vitro culture of retinal explants exposed to NMDA, we found that 
NPY pre-treatment prevented NMDA-induced cell death through activation of Y1 and Y5 
receptors. In an animal model of retinal ischemia-reperfusion (I-R) injury, pre-treatment with 
NPY was not able to prevent cell death or rescue RGCs. In summary, we found clear 
modulatory effects of NPY at the level of RGCs, and Y1 receptor appears to have a predominant 
role. However, further studies are needed to evaluate whether NPY neuroprotective action 
translates to in vivo models of retinal degenerative diseases. 
Sildenafil (ViagraTM), a cyclic guanosine monophosphate (cGMP)-specific 
phosphodiesterase type 5 inhibitor, is widely used for the treatment of erectile dysfunction 
and pulmonary arterial hypertension. Clinical studies reported transient visual impairments in 
patients after a single dose sildenafil ingestion, suggesting the implication of RGCs, since these 
cells convey visual information to the brain centres of visual processing. However, the effect 
of sildenafil on the RGC light responses is not fully understood. Using a MEA technique, in the 
second part of this study, we evaluated the effect of sildenafil on RGC light responses in ex 
vivo retinas. Under continuous perfusion, sildenafil citrate (0.3 to 30 µM) was applied to 
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retinal preparations during 10 to 60 min followed by sildenafil washout. High concentration 
(30 µM) of sildenafil reversibly decreased the magnitudes of both ON- and OFF-type RGC light 
responses, and in 50% of RGCs, light responses were completely supressed. Sildenafil also 
greatly increased the latency of ON- and OFF-types of light responses. We provide the 
evidence that extended exposure to sildenafil and repeated light stimulation potentiates drug 
effects and delays recovery. 
In conclusion, we show that MEA recordings in ex vivo retinas might be a valuable 
method to understand how RGC circuitry can be affected by different drug treatments. This 
understanding is relevant to the development of neuroprotective strategies needed for retinal 
degenerative diseases, namely glaucoma, where no available treatment can effectively stop 
the progression of RGC death. 
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Resumo 
 
O neuropeptídeo Y (NPY) é um neuromodulador no sistema nervoso central, capaz de 
exercer efeitos neuroprotetores. O NPY é expresso na retina de mamíferos mas a sua 
localização, e dos seus recetores, e o seu potencial efeito neuromodulador na retina continua 
pouco estudado. A morte das células ganglionares da retina (CGR) é uma das principais 
caraterísticas de doenças degenerativas da retina, particularmente do glaucoma. Neste 
trabalho, verficámos a presença de mRNA e immunoreatividade para o NPY e os recetores do 
NPY em preparações purificadas de CGR. Também avaliámos o efeito da ativação de recetores 
do NPY nos níveis intracelulares de cálcio livre – [Ca2+]i, e na formação de potenciais de ação, 
utilizando culturas purificadas de CGR e em preparações de retina ex vivo. Os potenciais de 
ação gerados pelas CGR foram registados com uma matriz de elétrodos. A aplicação de NPY 
atenuou o aumento da [Ca2+]i induzido por glutamato via ativação do recetor Y1. Além disso, 
a ativação dos recetores Y1/Y5 induziu um aumento da resposta inicial das CGR tipo-OFF após 
estimulação luminosa, embora não tenha alterado a atividade espontânea das CGR. A ativação 
dos recetores Y1 inibiu o aumento da formação de potenciais de ação pelas CGR após 
estimulação com N-metil-D-aspartato (NMDA). Estes resultados sugerem que a ativação dos 
recetores Y1, ao nível da camada plexiforme interna ou da camada plexiforme externa da 
retina modula as propriedades do campo recetivo das CGR. Ao expor explantes de retina in 
vitro a NMDA verificámos que o pré-tratamento com NPY foi capaz de prevenir a morte celular 
induzida pelo NMDA através da ativação dos recetores Y1 e Y5. Num modelo animal de 
isquémia-reperfusão, o pré-tratamento com NPY não preveniu a morte das CGR. Em resumo, 
identificámos efeitos modulatórios do NPY ao nível das CGR, em que a ativação dos recetores 
Y1 parece ter um papel central. Contudo, são necessários mais estudos com a finalidade de 
avaliar o potencial neuroprotetor do NPY in vivo em modelos de doenças degenerativas da 
retina. 
 O sildenafil (ViagraTM) é um inibidor da fosfodiesterase tipo 5, amplamente usado no 
tratamento da disfunção erétil e na hipertensão arterial pulmonar. Alguns estudos clínicos 
reportaram deficiências visuais temporárias em doentes que utilizavam sildenafil, o que 
sugere o possível envolvimento das CGR, uma vez que são estas células que transmitem a 
informação visual para centros cerebrais responsáveis pelo processamento da visão. Contudo, 
o efeito do sildenafil nas respostas das CGR a estímulos luminosos está pouco esclarecido. Na 
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segunda parte deste estudo, utilizámos uma matriz de elétrodos para avaliar o efeito do 
sildenafil nas respostas das CGR à luz em retinas ex vivo. Com perfusão constante, aplicámos 
concentrações crescentes de sildenafil (0,3 – 30 µM) durante períodos de 10 ou 60 minutos, 
seguidos de solução de lavagem. Uma concentração elevada de sildenafil (30 µM), provocou 
um decréscimo reversível na magnitude das respostas das CGR à luz, do tipo ON ou OFF das 
CGR, sendo que em 50% das CGR as respostas à luz foram completamente inibidas, embora 
reversivelmente. Além disso, o sildenafil provocou um aumento das latências das respostas 
do tipo ON e OFF. Também verificámos que a exposição prolongada a sildenafil, 
simultaneamente com estimulação luminosa, potencia os efeitos do fármaco e dificulta a 
recuperação das respostas das CGR à luz. 
 Assim, concluímos que o registo da atividade das CGR com uma matriz de elétrodos 
em retinas ex vivo é um método eficiente para estudar o modo como as CGR poderão ser 
afetadas por diferentes fármacos. Esta avaliação é importante para o desenvolvimento de 
estratégias neuroprotetoras necessárias para o tratamento de doenças degenerativas da 
retina, nomeadamente o glaucoma, para o qual não existe um tratamento eficaz, capaz de 
impedir a morte das CGR. 
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1.1 – The retina 
 
 
1.1.1 – Anatomy of the retina 
 
The retina is a thin tissue composed of a highly organized neuronal network inside of 
the eyeball (Fig. 1.1 A). It is part of the CNS and is responsible for transforming outside world 
natural scenes into meaningful information to the brain. The retina is basically formed by 
three main layers of neurons (Fig. 1.1 B), which cell somas are packed into three nuclear layers: 
outer nuclear layer (ONL), inner nuclear layer (INL), and ganglion cell layer (GCL). These retinal 
neurons communicate through chemical and electrical synapses forming two tightly organized 
plexiform layers: outer plexiform layer (OPL) and inner plexiform layer (IPL). The ONL is 
composed of cell somas of photoreceptors: rods and cones. The rods operate mainly in dim 
light conditions and cones in daylight, being responsible for coloured and fine resolution 
vision. The INL is composed of cell somas of bipolar cells, horizontal cells, and amacrine cells. 
The GCL comprise the cell somas of displaced amacrine cells and retinal ganglion cells (RGCs) 
whose axons compose the nerve fibre layer (NFL), leaving the eyeball and forming the optic 
nerve that conveys the information from the retina to the brain visual centres. Within the OPL 
the photoreceptor terminals synapse with bipolar cell and horizontal cell dendrites. The IPL is 
a complex layer of synaptic connections, organized in five strata. In this layer, different sub-
types of bipolar cells, amacrine cells, and RGCs form synapses in specific strata. This complex 
plexiform layer is responsible for the final tuning of output visual information which is coded 
in the form of action potential patterns (spiking activity) by RGCs. In addition to neurons, other 
cell types compose and support the retina. An epithelial cell layer in the outermost part, the 
retinal pigmented epithelium (RPE), is responsible for recycling outer segments of 
photoreceptors, among other important functions such as absorbing excessive light and 
transporting nutrients and ions from choriocappilaries. Retinal glial cells, namely microglia, 
astrocytes, and Müller cells (Fig. 1.1 C) exert an important role in supporting and regulating 
retinal physiology. 
The photoreceptors are supplied by the choroidal blood vessels while inner retina is 
nourished by the retinal artery, which then branches into three capillary networks throughout 
the retina. An important feature of retinal vascular network is the presence of tight junctions 
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between endothelial cells of the retinal capillaries. In addition, epithelial cells of RPE also 
exhibit tight junctions. Therefore, the RPE and retinal capillaries form a blood-retinal barrier 
(BRB) that tightly regulates the transport of molecules into the retina. The RPE forms the outer 
BRB, while retinal capillaries form the inner BRB. The BRB is an important player in the retinal 
defence mechanisms against circulating toxins (Siu et al., 2008). 
Figure 1.1. Anatomy of the retina. (A) The retina is a thin tissue inside the eyeball (Widmaier et al., 
2004). (B) There are six types of neurons in the mammalian retina: 1 – rods, 2 – cones, 3 – horizontal 
cells, 4 – bipolar cells, 5 – amacrine cells, 6 – retinal ganglion cells (RGCs). OS/IS, outer and inner 
segments of rods and cones; ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear 
layer; IPL, inner plexiform layer; GCL, ganglion cell layer; NFL, nerve fibre layer. Adapted from 
Wassle (2004). Müller glial cells (C) extend throughout the retinal thickness Adapted from Ahmad 
et al. (2011). 
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1.1.2 – Phototransduction 
 
 Phototransduction is the process by which photoreceptors convert photons absorbed 
by photopigments into synaptic response at photoreceptor terminals (Fig. 1.2). The presence 
of photopigments in photoreceptor outer segments allows these cells responding to light. 
Photopigments consists of an opsin isoform and a covalently attached chromophore derived 
from vitamin A (11-cis retinal). 
Figure 1.2. Phototransduction cascade. After rhodopsin (R) activation by light, the subsequent 
transducin (T) and phosphodiesterase (P) activation triggers cGMP hydrolysis. The drop in cGMP 
leads to the closure of cyclic nucleotide-gated (CNG) channels which results in membrane 
hyperpolarization. Then, the activation of guanylate cyclase-activating protein (GCAP) and 
guanylate cyclase (GC) restores the cGMP levels and membrane depolarizes. NCKX, Na+/Ca2+, K+ 
exchanger; PM, plasma membrane (Chen, 2005). 
 
In the dark, the photoreceptor cell membrane is depolarized and the neurotransmitter 
glutamate is being released. The first step of phototransduction occurs when light isomerizes 
the 11-cis bond of the retinal to the all-trans configuration. This isomerization triggers a 
conformational change in rhodopsin (R) which becomes active in a conformation state called 
metarhodopsin II (R*). R* catalyses the exchange of guaŶosiŶe ϱ’-triphosphate (GTP) for 
guaŶosiŶe ϱ’-diphosphate (GDP) oŶ the α-subunit of the heteromeric G protein transducin 
(TαGDPβγ). Activated transducin α-subunit (T*αGTPͿ dissoĐiates froŵ traŶsduĐiŶ βγ-subunits (Tβγ) 
aŶd ďiŶds to the iŶhiďitorǇ γ-subunit of the tetrameric phosphodiesterase - PDE - (PαβγϮ). The 
uninhibited catalytic subunit of PDE (P*αβ) hydrolyzes cGMP into guanosine ϱ’-
monophosphate (ϱ’-GMP). The drop of intracellular cGMP concentration closes the cyclic 
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nucleotide-gated (CNG) channel located at the plasma membrane, blocking the entry of Na+ 
and Ca2+, which results in membrane hyperpolarization and glutamate release decrease. Since 
the Na+/Ca2+, K+ exchanger (NCKX) at the cell membrane is not light sensitive and Ca2+ 
extrusion continues while Ca2+ entry through the CNG channel is blocked, the 
phototransduction leads to a decline in intracellular Ca2+ concentration [Ca2+]i. The drop in 
[Ca2+]i leads to the interaction between guanylate cyclase-activating protein (GCAP) and 
guanylate cyclase (GC) resulting in GC activation. This restores the levels of cGMP, so CNG 
channels open and the membrane depolarization is restored (Chen, 2005). 
 
 
1.1.3 – Retinal circuitry and transmission of visual signals 
 
 A simple representation of signal flow in the retina is the division in the vertical 
pathway (photoreceptor – bipolar cell – RGC), using the excitatory neurotransmitter 
glutamate, and in the lateral pathway, associated with horizontal cell and amacrine cell 
activity, which provide lateral inhibition using mainly γ-aminobutyric acid (GABA). However, 
multiple pathways operate simultaneously extending the understanding of the retinal 
circuitry, and will be detailed below. 
Rod photoreceptors contain only one type of photopigment - rhodopsin - most 
sensitive to wavelengths around 505 nm. In cone photoreceptors, different photopigments 
(photopsins) are found, based on their spectral sensitivity (Fig. 1.3 A). The type of pigment 
gives the name to the cone photoreceptor. Most mammals contain two types of cones, 
namely middle wavelength sensitive (green, M-cones) and short wavelength sensitive (blue, 
S-cones). In addition to M- and S-cones, primates also contain long wavelength sensitive cones 
(red, L-cones). The processing of visual information in the retina starts at the OPL where 
photoreceptors synapse with bipolar cells and horizontal cells through special synapses called 
pedicles for cones and spherules for rods. Is at this level that the two major functional visual 
pathways, ON and OFF, are generated and run in parallel towards brain visual centres. This 
dichotomy, ON and OFF, is based on two different types of bipolar cells. 
OFF-type bipolar cells that respond to light with the same polarity as the 
photoreceptor, i.e. bipolar cells are depolarized in the dark and hyperpolarize upon light 
stimulation. This connection is named sign conserving synapse. In contrast, ON-type bipolar 
cells respond to light with an inverted polarity, i.e. bipolar cells are hyperpolarized in the dark 
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and depolarized upon light stimulation – sign inverting synapses. The presence of different 
glutamate receptors at bipolar dendritic terminals determines the type of bipolar cell. In the 
OFF-type bipolar cells the glutamate released by photoreceptors in the dark activates 
excitatory ionotropic glutamate receptors (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA)-Kainate type), resulting in membrane depolarization. 
In contrast, in the ON-type bipolar cells, the glutamate released by photoreceptors in 
the dark activates inhibitory metabotropic glutamate receptor 6 (mGluR6), which results in 
membrane hyperpolarization (Nakajima et al., 1993). Since each bipolar cell contact many 
photoreceptors, the relative amount and location of ON- and OFF- connections determine the 
centre-surround organization of the receptive field and, thus, define the respective cell type: 
ON-centre or OFF-centre bipolar cell. The ON and OFF dichotomy and the centre-surround 
organization of the receptive fields are maintained at IPL resulting in ON-centre and OFF-
centre RGC types. 
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Figure 1.3. Cone and rod pathways. (A) Cone photoreceptor types are determined by their 
photopigment spectral sensitivities. The absorption spectrum is shown for each photopigment. 
Adapted from Hoon et al. (2014). Dashed trace represents rhodopsin. In addition to M-cones 
(middle wavelength, green) and S-cones (short wavelength, blue), primates also contain L-cones 
(long wavelength, red). (B) Two major cone pathways, ON and OFF, run in parallel to RGCs. Adapted 
from Balasubramanian and Sterling (2009). OFF bipolar cells make sign conserving contacts with 
cone photoreceptors whereas ON bipolar cells make sign inverting contacts with cone 
photoreceptors. Then, both bipolar cell types synapse with ON or OFF RGCs. (C) Rod photoreceptor 
signals reach ON and OFF channels at RGC level through multiple pathways. Adapted from Wassle 
(2004). ON1 and OFF1 represent classical pathways. Rods make sign inverting synapses (red arrows) 
with invaginating dendrites of rod bipolar cells (RB), which then contact AII amacrine cells through 
sign conserving synapses (green arrows). AII amacrine cells access simultaneously ON and OFF 
channels. They make gap junctions (electrical synapses) with ON cone bipolar cells, which in turn 
synapse with ON RGCs (ON1), and at the same time they make inverting synapses with the axons 
of OFF cone bipolar cells, which in turn synapse with OFF RGCs (OFF1). In the ON2 and OFF2 
pathways, the rod signals are transmitted to cones through gap junctions and then follow cone 
pathways to either ON or OFF RGCs, respectively. In the OFF3 pathway, OFF cone bipolar cells make 
direct synaptic contacts with the base of rod spherules and transfer this signal directly onto OFF 
RGCs. 
A B
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 The way photoreceptor signals access RGCs involves various pathways. Cone 
photoreceptors connect ON and OFF cone bipolar cells which in turn contact RGCs (Fig 1.3 B), 
whereas rod photoreceptors contact mainly ON rod bipolar cells that do not contact directly 
RGCs but instead use a particular type of amacrine cell – AII amacrine cell – which in turn 
contact ON and OFF cone bipolar cells and thus access RGCs (Fig. 1.3 C). 
However, in the last decades, alternative pathways have been identified (Fig. 1.3 C) 
broadening the knowledge of retinal complex circuitry (Wassle, 2004). Of special interest are 
the electrical synapses various retinal neurons are able to establish through gap junctions. The 
rod and cone photoreceptors contact via gap junctions allowing rod signals to access cone 
pathways (DeVries and Baylor, 1995). In addition, some OFF-cone bipolar cells make direct 
synaptic contacts with the base of rod spherules transferring this signal directly onto OFF RGCs 
(Soucy et al., 1998; Hack et al., 1999). 
Taking into account the neuronal diversity found in the mammalian retina (Fig. 1.4), 
one may anticipate the complexity of this neural structure in terms of anatomical arrangement 
and physiological interactions. In fact, more than different 50 neuronal types have been 
identified by structural criteria and many remain to be assigned to a specific visual function 
(Masland, 2001). In the circuitry depicted in Figure 1.3 C, it is clear that the processing of visual 
information in the retina involves mainly two stages, one at the OPL and the other at the IPL. 
At the OPL, horizontal cells make sign conserving synaptic contacts with photoreceptors, thus 
maintaining a relatively depolarized potential in the dark and then hyperpolarizing upon light. 
Horizontal cells mainly release GABA providing a negative feedback signal to photoreceptors. 
They play an important role in the generation of receptive field surrounds in bipolar cells 
(Dacey, 1999) adding an opponent signal that is spatially constrictive. Moreover, horizontal 
cell activity is regulated by signals from the IPL, which are transmitted via various molecules 
such as dopamine, nitric oxide, and retinoic acid. These signals contribute to the regulation of 
horizontal cells under different light conditions (Twig et al., 2003).  
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Figure 1.4. Neuronal diversity of mammalian retina. Based on receptive field size and dendritic 
stratification various neuronal classes are identified. The retina is composed of wide-field cells and 
narrow-field cells, though wide-field are less numerous. The numbers of cells are distributed 
uniformly among the different classes. Note that amacrine cells and RGC dendritic terminals exhibit 
various stratification modalities in IPL, e.g. monostratified and bistratified (Masland, 2001). 
 
 At the second stage of image processing at the IPL, bipolar cell terminals, RGC 
dendrites, and amacrine cells establish contacts. At the RGC level, visual information is 
computed in the form of spike trains, and, as abovementioned, two basic channels, ON and 
OFF, form the major retina output to the brain. ON-centre RGCs are maximally activated when 
a spot of light is presented to the centre of their receptive field, and they are maximally 
inhibited when light stimulation is presented on the receptive field periphery. OFF-centre 
RGCs respond to light stimulation in an opposite way. Because the contacts between bipolar 
cell and RGCs are sign conserving, the ON- and OFF-response origin is essentially determined 
by the bipolar cell types contacting with each individual RGC (Westheimer, 2007). Amacrine 
cells convey additional information to IPL circuitry. Several neurotransmitter molecules are 
used by amacrine cells, such as GABA, glycine, acetylcholine, dopamine, and serotonin (Kolb, 
1995). Using specific markers for each neurotransmitter-containing amacrine cell, it is possible 
to identify specific strata on IPL, since their dendrites ramify in narrow bands (Haverkamp and 
Wassle, 2000). Within these different strata, specific aspects of light signals are processed, 
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where amacrine cells play a predominant role (Wassle, 2004). In fact, to extract meaningful 
features from natural scenes by the brain, part of the necessary neuronal computation of 
visual information is performed by the retina. As above mentioned, different retinal neurons 
are involved in this process, though the output signal is carried out only by RGC spiking activity. 
In Figure 1.5 are exemplified various specific visual tasks performed by retinal circuitry, such 
as detection of dim light flashes, sensitivity to texture motion, detection of differential motion 
and approaching motion, the rapid encoding of spatial structures, and the ability to switch 
circuits (Gollisch and Meister, 2010). These tasks might be understood as answers to particular 
challenges shared by many animals, such as the need to detect dim lights and the need to 
detect moving objects.  
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Figure 1.5. Neural computations in retinal circuitry. All computations within retinal circuitry 
involves different retinal cell types, namely bipolar cells, amacrine cells, and RGCs, though the 
output signal is carried out by RGC spiking activity. (A) Detection of dim light flashes originates in 
rod-to-rod bipolar pathway. Rod bipolar cells pool over many rod photoreceptors. (B) Sensitivity to 
texture motion results from the selective activation of a particular RGC when a fine grating shifts in 
either direction within the RGC receptive field (circle). (C) The detection of differential motion is 
attributed to an object-motion-sensitive RGC that remains silent under global motion of the entire 
image, but fires when the image patch in its receptive field moves differently from the background. 
(D) The detection of approaching motion is assigned to a certain type of RGC that responds strongly 
to the visual pattern of an approaching dark object. (E) The rapid encoding of spatial structures is 
based on spike latencies of specific RGCs. RGCs with receptive fields (circles) in a dark region fire 
early, and those in a bright region fire late. (F) The ability to switch between circuits is driven by a 
certain type of wide-field amacrine cell, activated during rapid image shifts in the periphery, which 
selectively gates one of two potential input signals. Adapted from Gollisch and Meister (2010). 
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C D
E F
General Introduction 
 
21 
 
1.1.4 – Circadian visual system 
 
In mammals, in addition to classical rod and cone photoreceptors, a third type of 
photosensitive neuron is present and define a particular type of intrinsically photosensitive 
RGCs (ipRGCs), which mediate non-image-forming visual functions such as pupillary light 
reflex and circadian photoentrainment. The photosensitivity of ipRGCs requires the expression 
of melanopsin, a photopigment with peak absorbance around 484 nm (Berson et al., 2002). 
The ipRGCs project predominantly to the suprachiasmatic nuclei (SCN) of the hypothalamus 
(Hattar et al., 2002), which is the primary circadian oscillator in mammals. Indeed, ipRGCs play 
an important role in photoentrainment, a process by which the light/dark cycle synchronizes 
the SCN central oscillator (Morin and Allen, 2006). This central oscillator then synchronizes 
peripheral circadian clocks distributed in other mammalian tissues, such as the retina (Tosini 
et al., 2008), multiple brain regions (Abe et al., 2002), and many peripheral tissues (Damiola 
et al., 2000). The retinal intrinsic circadian oscillator is involved in circadian rhythms of the 
inner retinal circuitry (Storch et al., 2007). The retinal circadian pacemaker property is assured 
by the expression in multiple types of retinal neurons of key elements of the circadian 
autoregulatory gene network ͞ĐloĐk geŶes͟ like Period 1 and 2, Cryptochrome 1 and 2, and 
Clock and Bmal 1 (Ruan et al., 2006). 
 
 
1.1.5 – Glaucoma and retinal ganglion cell death 
 
Pathologies of the neural retina represent a major cause of visual impairment and 
blindness worldwide and the development of effective neuroprotective strategies is an 
important challenge in ophthalmology research. In order to evaluate the effectiveness of 
putative neuroprotective compounds, various in vitro and animal models of neurotoxicity, 
such as retinal ischemia, exposure to glutamate or NDMA, optic nerve crush, and glaucoma 
models characterized by increased intraocular pressure (IOP) have been used (Barkana and 
Belkin, 2004). 
In particular, glaucoma is the major cause of irreversible blindness worldwide, 
estimated to affect approximately 80 million people by 2020 (Quigley and Broman, 2006), and 
the search for neuroprotective strategies to prevent RGC death is an important challenge 
(Baltmr et al., 2010). Glaucoma is a multifactorial disease characterized mainly by the 
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progressive degeneration of RGCs and their axons. Clinically, a characteristic cup excavation 
due to alterations of the connective tissue at the optic disc are coincident with the initial 
abnormalities in both human and experimental glaucoma (Quigley et al., 1981). Although 
increased IOP is a major risk factor, several pathophysiological mechanisms have been 
associated with the progression of the disease (Cheung et al., 2008). These include 
excitotoxicity, protein misfolding, mitochondrial dysfunction, oxidative stress, inflammation, 
and neurotrophin deprivation. Currently, the medical management of glaucoma is based in 
lowering IOP, but although effective control of IOP is many times achieved, the progression of 
RGC loss is not prevented (Geringer and Imami, 2008). Therefore, pharmacological therapies 
targeting pathophysiological mechanisms, others than elevated IOP, as above mentioned, 
have been extensively evaluated in in vitro and animal models of RGC degeneration (Chidlow 
et al., 2007; Baltmr et al., 2010). The in vitro studies include mainly cultured RGCs and cultured 
retinal explants exposed to different stimuli, such as NMDA or glutamate (Pang et al., 1999; 
Dun et al., 2007), neurotrophic withdrawal (Johnson et al., 1986; Hu et al., 2010), and elevated 
hydrostatic pressure (Sappington et al., 2006; Ishikawa et al., 2010). The different stimuli used 
in in vitro studies aimed to mimic isolated characteristics of glaucoma pathophysiology. In 
addition, various animal models have been used to evaluate the potential neuroprotective 
effects of different drug treatments against RGC death. These include animal models where 
IOP is chronically elevated by blocking the aqueous humour outflow. This has been achieved 
by injecting a hypertonic saline solution into the episcleral veins (Morrison et al., 1997), 
cauterization of episcleral veins (Shareef et al., 1995; Hernandez et al., 2008), or injection of 
polystyrene microbeads into the anterior chamber (Sappington et al., 2010) among other 
techniques. Other animal models include mainly optic nerve crush (Schuettauf et al., 2000) or 
optic nerve transection (Kikuchi et al., 2000), injection of NMDA or glutamate directly into 
vitreous humour (Nash et al., 2000; Santos-Carvalho et al., 2013b), and retinal I-R injury (Kapin 
et al., 1999; Chidlow et al., 2002). 
Although these studies have contributed to significant advances in understanding both 
the pathogenic and neuroprotective mechanisms involved in glaucoma and its treatment, 
translating experimental drug treatments to glaucoma patients has not been successfully 
achieved. In fact, the clinical trial of memantine (a NMDA receptor antagonist, anti-
excitotoxic) in glaucoma patients have failed, likely due to the multifactorial nature of 
glaucoma (Osborne, 2009). This finding suggests that neuroprotective compounds with 
multiple modes of action might be more efficient.  
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1.2 – Neuropeptide Y 
 
 
1.2.1 – Structure and biosynthesis 
 
Neuropeptide Y (NPY) is a 36 amino acid peptide that was first isolated from porcine 
brain (Tatemoto, 1982; Tatemoto et al., 1982). NPY is widely expressed in the CNS and acts as 
a neurotransmitter/neuromodulator or neurohormone. In the periphery it is mainly found in 
sympathetic nerve terminals where is co-released with norepinephrine and adeŶosiŶe ϱ’-
triphosphate (ATP) (Morris, 1999; Wier et al., 2009). During the last three decades NPY has 
been associated with a multitude of physiological functions such as feeding behaviour and 
energy homeostasis (Chambers and Woods, 2012; Sohn et al., 2013), regulation of 
emotionality and behavioural stress responses including drug addiction (Heilig, 2004; Koob, 
2008; Hirsch and Zukowska, 2012), regulation of circadian rhythm (Moore and Card, 1990; 
Yannielli and Harrington, 2004), bone physiology (Lee and Herzog, 2009; Khor and Baldock, 
2012), neurogenesis (Hansel et al., 2001; Malva et al., 2012), and immune response 
(Prod'homme et al., 2006; Bedoui et al., 2007; Wheway et al., 2007; Dimitrijevic and 
Stanojevic, 2013). NPY belongs to a family of highly conserved peptides which includes also 
pancreatic polypeptide (PP), and peptide YY (PYY), all with 36 amino acid residues (Fig. 1.6 A, 
B) (Michel et al., 1998), which bind to seven transmembrane G protein-coupled receptors 
(GPCRs) named NPY receptors, Y1, Y2, Y4, and Y5 in humans. 
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Figure 1.6. NPY family of peptides. (A) Structure of porcine PYY (pPYY), porcine NPY (pNPY), and 
bovine PP (bPP). Adapted from Lerch et al. (2004). (B) Amino acid sequences of porcine NPY (pNPY), 
human PYY (hPYY), and human PP (hPP) (Walther et al., 2011). 
 
The high homology between these peptides results from whole genome and individual 
gene duplication events occurred early in vertebrate evolution, a common feature for other 
peptides (Larhammar et al., 2009). The first duplication is believed to have generated NPY and 
PYY, and a second duplication generated PP from PYY (Cerda-Reverter and Larhammar, 2000; 
Conlon and Larhammar, 2005). These peptides have been associated with a hairpin-like spatial 
arrangement called ͞PP-fold͟, consisting of an N-terminal polyproline helix (residues 1-8), a 
consecutive turn and a C-terŵiŶal α-helix (residues 14-31) arranged in a U-shape tertiary 
structure (Blundell et al., 1981). However, nuclear magnetic resonance (NMR) studies found 
that the N-terminal is flexible and does not form hairpin-like fold under physiological 
conditions (Bader et al., 2001; Lerch et al., 2002; Lerch et al., 2004). Particularly, for NPY, 
fluorescence resonance energy transfer (FRET) studies confirmed that the N-terminal does not 
fold back onto C-terŵiŶal α-helix in solution (Bettio et al., 2002; Haack and Beck-Sickinger, 
2009). 
The NPY gene is located on human chromosome 7p15.1. It is composed of four exons 
and results in the synthesis of a 97-amino-acid pre-pro-NPY (Fig. 1.7) (Minth et al., 1984). The 
signal peptide of pre-pro-NPY is cleaved in the endoplasmic reticulum by a signal peptidase, a 
common feature to most pre-pro-peptides (Dores et al., 1996). In the following step, pro-NPY 
A
B
pPYY pNPY bPP
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is proteolytically processed at a dibasic site by prohormone convertases into the C-terminal 
peptide of NPY (CPON) and NPY1-39 (Hook et al., 1996; Funkelstein et al., 2008; Funkelstein et 
al., 2012). This is further processed by carboxypeptidase to NPY1-37. The processing and C-
terminal amidation of NPY is aĐĐoŵplished ďǇ peptidǇlglǇĐiŶe α-amidating monooxygenase. 
The amidation of NPY is essential for biological activity and prevents degradation by 
carboxypeptidases. Mature NPY (NPY1-36) is rapidly cleaved in serum into three main 
fragments: NPY3-36, NPY3-35, and NPY2-36 (Medeiros and Turner, 1996; Abid et al., 2009). NPY1-
36 is predominantly cleaved into NPY3-36 by dipeptidyl peptidase IV (DPPIV), and through a 
slower process by aminopeptidase P into NPY2-36. Both of these peptides loose the affinity for 
Y1 receptor, retaining high affinity for Y2 and Y5 receptors. In addition, a fraction of NPY3-36 is 
further degraded by plasma kallikrein into NPY3-35. This later peptide does not bind to any of 
NPY receptors, thus representing a possible major metabolic clearance product of NPY3-36.  
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Figure 1.7. Biosynthesis of NPY. NPY gene is composed of four exons and results in the synthesis of 
a 97-amino-acid pre-pro-NPY. After a series of proteolytic steps and final C-terminal amidation, the 
mature and biological active NPY1-36 is formed. bp, base pairs; nt, nucleotides; UTR, untranslated 
region; CPON, C-terminal peptide of NPY (Silva et al., 2002).  
 
 
1.2.2 – Neuropeptide Y receptors 
 
Similarly to the ligand peptides NPY, PYY, and PP, the various NPY receptors result from 
chromosomal and gene duplication events during evolution (Larhammar and Salaneck, 2004). 
Interestingly, mammals have lost some NPY receptors, namely Y7 (Fredriksson et al., 2004) and 
Y8 (Lundell et al., 1997; Larsson et al., 2008), which have arisen in the ancestor of the jaw 
vertebrates (Larhammar and Bergqvist, 2013). Functional active NPY receptors, Y1, Y2, Y4, and 
Y5, in humans and rats, as for all GPCRs, consist of an extracellular N-terminus, seven 
traŶsŵeŵďraŶe α-helices connected by three intracellular and three extracellular loops, and 
an intracellular C-terminus. The mRNA presence evaluated by in situ hybridization for different 
NPY receptors, Y1, Y2, Y4, and Y5, together with functional autoradiography, show that all the 
receptors are widely distributed throughout the rat brain, especially in regions such as 
hypothalamus, hippocampus, and amygdala (Lynch et al., 1989; Parker and Herzog, 1999). 
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The Y1 receptor was first cloned from rat brain in 1990 (Eva et al., 1990). In humans, Y1 
receptor gene is located on chromosome 4q31.3-q32 (Herzog et al., 1993). The following 
agonist order of poteŶĐǇ of NPY ≥ PYY ≥ [Pro34]substituted analogue >> C-terminal fragment > 
PP has been found for Y1 receptor was reported (Michel et al., 1998). Functional 
autoradiography and immunohistochemistry experiments revealed an abundant presence of 
Y1 receptor in several brain regions such as cerebral cortex, hippocampus, hypothalamus, 
thalamus, amygdala, and brainstem (Shaw et al., 2003; Wolak et al., 2003). 
The Y2 receptor was first cloned from human SMS-KAN cells (Rose et al., 1995). In 
humans, Y2 receptor gene is located on chromosome 4q31 (Ammar et al., 1996). The following 
agoŶist order of poteŶĐǇ of NPY ≈ PYY ≥ C-terminal fragment >> [Pro34]substituted analogue > 
PP was reported (Michel et al., 1998). Positron emission tomography (PET) neuroimaging in 
pig brain showed the presence of Y2 receptor mainly in thalamus, caudate nucleus, 
hippocampus, and cerebellum (Winterdahl et al., 2014). 
 In various systems and organs such as rat CNS (Grundemar et al., 1991), lung 
(Hirabayashi et al., 1996), and adrenals (Bernet et al., 1994), it was reported the presence of 
binding sites or responses where NPY is considerably more potent than PYY, and these sites 
has been referred as Y3. However, since no receptor has been cloned and no specific agonist 
or antagonist has been described so far, this receptor might not exist, and these sites or 
responses were proposed to be referred as ͞putatiǀe Y3͟ (Michel et al., 1998). 
The Y4 receptor was first cloned froŵ a huŵaŶ geŶoŵiĐ liďrarǇ aŶd Ŷaŵed as ͞PPϭ͟ 
due to the high affinity (13.8 pM, Ki) to PP (Lundell et al., 1995), while NPY and PYY binds with 
9.9 and 1.44 nM affinity, respectively. In humans, the gene encoding for Y4 receptor is located 
on chromosome 10q11.2 (Darby et al., 1997). Although in the periphery Y4 receptor is highly 
expressed in colon, small intestine, pancreas, and prostate (Lundell et al., 1995), in the brain 
low levels are detected, and restricted to brain stem, hypothalamus, and hippocampus (Parker 
and Herzog, 1999). 
The Y5 receptor was initially cloned from rat hypothalamus (Gerald et al., 1996; Hu et 
al., 1996) and the corresponding gene in human localized on chromosome 4q31, in the same 
location as human Y1 receptor gene, but in opposite orientation (Gerald et al., 1996; Borowsky 
et al., 1998). The folloǁiŶg agoŶist order of poteŶĐǇ of NPY ≥ PYY ≈ [Pro34]substituted analogue 
≈ NPY2-36 ≈ PYY3-36 >> NPY13-36 was reported in in vitro functional assays. Since this 
pharmacological profile was consistent with in vivo food intake assays and mRNA for Y5 
receptor was localized in areas of hypothalamus known to regulate food intake, the Y5 
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receptor was soon suggested as the primary mediator of NPY-induced feeding (Gerald et al., 
1996). In rat brain, autoradiographic assays revealed Y5 receptor binding sites in olfactory 
bulb, lateral septum, anteroventral thalamic nucleus, hippocampal CA3, nucleus tractus 
solitarius, and area postrema (Dumont et al., 1998). Using immunohistochemistry, the 
presence of Y5 receptor imunoreactivity was found in cerebral cortex, hippocampus, 
hypothalamus, thalamus, amygdala, and brainstem (Wolak et al., 2003). 
The y6 was first cloned from mouse genomic DNA (Weinberg et al., 1996). The 
homologous gene in humans was localized in chromosome 5q31 (Gregor et al., 1996). 
However, compared to mouse, the human sequence differs by a frame shift mutation which 
causes a stop codon predicting a truncated protein, though this later has not been successfully 
expressed (Gregor et al., 1996). Several sequences from primate species contain this stop 
codon suggesting the receptor function has been inactivated early in primate evolution 
(Matsumoto et al., 1996). In fact, no physiological correlate has been reported for the cloned 
y6 receptor (Michel et al., 1998). 
 
 
1.2.3 – Intracellular signalling pathways 
 
NPY receptors are all coupled to heterotrimeric G-proteins, mainly Gi/0 family, and their 
activation leads mainly to the inhibition of adenylate cyclase (Fig. 1.8), regulation of K+ and 
Ca2+ channels, and the activation of extracellular-signal-regulated kinase 1 and 2 (ERK1/2) 
(Shimada et al., 2012). The inhibition of adenylate cyclase, which results in decreased 
intracellular cyclic adenosine monophosphate (cAMP) levels, is found in most tissues and cell 
types studied, and also in all cloned NPY receptors upon heterologous expression (Gerald et 
al., 1996; Weinberg et al., 1996). 
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Figure 1.8. Examples of NPY receptor-mediated transduction cascades. NPY is frequently present 
in neurons synthesizing GABA. Y1 receptors are located mainly postsynaptically, and Y2 receptors 
are loĐated ďoth presǇŶaptiĐallǇ aŶd postsǇŶaptiĐallǇ. NPY reĐeptor aĐtiǀatioŶ, ǀia Gα suďuŶit, leads 
to inhibition of adenylate cyclase (AC), and via Gβγ suďuŶits leads to iŶhiďitioŶ of presǇŶaptiĐ N- 
and P/Q-type Ca2+ channels involved in the release of glutamate and other neurotransmitters. 
PostsǇŶaptiĐallǇ, NPY reĐeptor aĐtiǀatioŶ, ǀia Gβγ suďuŶits, leads to aĐtiǀatioŶ of G-protein-coupled 
inwardly-rectifying K+ channels (GIRKs). Other pathways include activation of mitogen-activated 
protein kinases (MAPKs) and phospholipase C (PLC) (Benarroch, 2009). 
 
NPY-mediated regulation of Ca2+ includes the activation or inhibition of Ca2+ channels 
(Ewald et al., 1988; Michel and Rascher, 1995). In particular, facilitation of L-type voltage-
dependent Ca2+ channels (VDCCs) via Gαs-protein and inhibition of N- and P/Q-VDCCs ǀia Gαi-
protein has been reported in submandibular ganglion neurons (Endoh et al., 2012). The 
control of Ca2+ channels, especially the inhibition of VDCC, has been reported to regulate 
neurotransmitter release in sympathetic nerve terminals (Toth et al., 1993), cortical nerve 
terminals (Wang, 2005), and hippocampus (Silva et al., 2001). In some cell types, NPY receptor 
activation can mobilize Ca2+ from intracellular stores, which involve inositol triphosphate in 
some cells (Perney and Miller, 1989), but not in other cell types (Motulsky and Michel, 1988). 
The activation or inhibition of K+ channels has also been reported (Millar et al., 1991; Xiong 
and Cheung, 1995). Indeed, the activation of G-protein-coupled inwardly-rectifying K+ 
channels (GIRKs) has been reported in several brain regions such as hippocampus (Paredes et 
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al., 2003), thalamus (Sun et al., 2001; Sun et al., 2003), arcuate nucleus (Acuna-Goycolea et 
al., 2005), and amygdala (Sosulina et al., 2008). Activation of mitogen-activated protein kinase 
(MAPK) family members have also been reported in various cell types, such as cell lines 
expressing NPY receptors (Nie and Selbie, 1998), erythroleukemia cells (Keffel et al., 1999), 
adrenal chromaffin cells (Rosmaninho-Salgado et al., 2007; Rosmaninho-Salgado et al., 2009), 
adipocytes (Rosmaninho-Salgado et al., 2012), vascular cells (Shimada et al., 2012), 
neuroblastoma cells (Lu et al., 2010), and in retinal neural cells (Alvaro et al., 2008a) and retinal 
glial cells (Milenkovic et al., 2004). Furthermore, each NPY receptor has a distinct molecular 
mechanism responsible for the receptor trafficking processes, such as anterograde transport, 
internalization, and recycling, which contributes to receptor response and signalling (Babilon 
et al., 2013). In particular, internalization experiments showed that Y1, Y2, and Y4 receptor 
internalize at comparable rates, whereas the Y5 receptor internalized much slower upon 
agonist binding (Bohme et al., 2008). 
 
 
1.2.4 – Neuropeptide Y and neuropeptide Y receptors in the retina 
 
The presence of NPY in the retina has been extensively studied in various species, 
revealing a conserved pattern of NPY-immunoreactivity (ir) (Santos-Carvalho et al., 2014). 
After NPY discovery in 1982, immunohistochemistry studies assessing the presence and 
localization of NPY soon reported the existence of NPY-ir in the retina of trout, carp, goldfish, 
zebrafish, gilthead seabream, killifish, frog, pigeon, chicken, guinea-pig, rat, rabbit, pig, cat, 
dolphin, and baboon (Fig. 1.9) (Bruun et al., 1984; Osborne et al., 1985; Bruun et al., 1986; 
Verstappen et al., 1986; Muske et al., 1987; Bruun et al., 1991; Subhedar et al., 1996; Chen et 
al., 1999; Kang et al., 2001; Le Rouëdec et al., 2002; Mathieu et al., 2002; Pirone et al., 2008). 
In these species, a common pattern was found. NPY-ir was localized mainly to amacrine cells, 
with cell bodies in the innermost row of INL, which processes ramified in the IPL forming up 
to three distinct layers. 
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Figure 1.9. NPY immunoreactivity in the retina. Examples of NPY-ir in the frog retina (A, B) and rat 
retina (C, D). (A) Wholemount of frog retina showing NPY-ir cells and their dendrites. Adapted from 
Hiscock and Straznicky (1989). (B) Section of frog retina. NPY-ir dendrites ramify in strata 1, 3, and 
5 of IPL. Adapted from Bruun et al. (1986). (C) Wholemount of rat retina showing NPY-ir in emerging 
processes (fine arrows) from cell somas (open arrows) of amacrine cells. Adapted from Oh et al. 
(2002). (D) Section of rat retina. NPY-ir dendrites ramify in strata 1, 3, and 5 of IPL. Adapted from 
Oh et al. (2002). Scale bar: 100 µm in A and B, 50 µm in C and D. 
 
The NPY-ir has been studied in various species of frogs (Fig. 1.9 A, B) and it has been 
reported to appear during early larval life (Hiscock and Straznicky, 1989, 1990; Zhu and 
Gibbins, 1995). The NPY-ir is found in amacrine cells that co-localize with GABA (Main et al., 
1993), and a single report also demonstrated that NPY-ir can be found in Müller cells (Zhu and 
Gibbins, 1996). Interestingly, NPY-ir exhibit seasonal variations with higher concentration in 
the autumn and lower in the spring, and NPY release is increased upon light stimulation or 
depolarization (Bruun et al., 1991). In the cat retina, NPY-ir is found not only in amacrine cells 
but also in RGCs (Hutsler et al., 1993; Hutsler and Chalupa, 1994, 1995). 
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In mouse and rat retina, NPY-ir was reported to localize in cell bodies of amacrine cells 
in INL and displaced amacrine cells in GCL (Fig. 1.9 C, D), co-localizing mainly with GABA 
(Ferriero and Sagar, 1989; Sinclair and Nirenberg, 2001; Oh et al., 2002). The corresponding 
cell processes extended and ramified mainly in strata 1, 3, and 5 of IPL, and very occasionally 
in OPL (Oh et al., 2002). In human retina, NPY-ir was shown to be confined to a subset of 
amacrine cells and RGCs, which processes extend mainly in IPL and occasionally in OPL 
(Tornqvist and Ehinger, 1988; Straznicky and Hiscock, 1989; Jen et al., 1994; Jotwani et al., 
1994). Moreover, in primary cultures of rat retinal cells, NPY-ir is found in different rat retinal 
cells, namely neurons, endothelial cells, microglial cells, and in Müller cells (Alvaro et al., 
2007). Regarding NPY receptor localization in the retina, there are only a few studies 
addressing this issue. In human retina, transcripts for Y1, Y2, and Y5 receptors were detected 
in RPE (Ammar et al., 1998). The presence of mRNA for both NPY and NPY receptors (Y1, Y2, 
Y4, and Y5) has also been demonstrated in the rat retina (D'Angelo and Brecha, 2004; Alvaro 
et al., 2007) and NPY, Y1, and Y2 mRNA was detected in mouse retina (Yoon et al., 2002). Y1 
receptor-ir was detected in horizontal and amacrine cells of rat retina and in glial cells of 
diseased human retina (Canto Soler et al., 2002; D'Angelo et al., 2002), and immunoreactivity 
for Y1 and Y2 receptors was found in neurons and glial cells in cultured rat retinal cells (Santos-
Carvalho et al., 2013a). 
Besides these studies addressing the presence of NPY and NPY receptors in the retina, 
the role of NPY in this neural tissue remains unclear. NPY application was found to regulate 
neurotransmitter release of rabbit and chicken retinas (Bruun and Ehinger, 1993). Also, NPY 
attenuates depolarization-induced increase in intracellular free calcium concentration – [Ca2+]i 
– in primary retinal cell cultures (Alvaro et al., 2009). Moreover, NPY decreased depolarization-
dependent Ca2+ influx into bipolar cells via activation of Y2 receptors (D'Angelo and Brecha, 
2004), and in retinas with selective ablation of NPY-expressing amacrine cells, alterations on 
receptive field properties of RGCs were reported, though a direct effect of NPY was not 
demonstrated (Sinclair et al., 2004). In addition, other studies have suggested the involvement 
of NPY and Y1 receptor activation in the regulation of osmotic Müller glial cell swelling in the 
rat retina (Uckermann et al., 2006; Linnertz et al., 2011).  
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1.2.5 – Neuroprotective actions of neuropeptide Y 
 
Targeting NPY receptors has been reported to exert neuroprotective actions in several 
systems. In fact, NPY receptors have been regarded as potential therapeutic targets in the 
brain, namely for epilepsy (Xapelli et al., 2006). Several studies have evaluated the 
neuroprotective potential of NPY or NPY receptor activation after exposure to glutamatergic 
agonists which have been used to induce an excitotoxic insult in vitro or in vivo. Using 
organotypic hippocampal slice cultures, the activation of Y1, Y2, or Y5 receptor was found to 
prevent kainate or AMPA-induced neuronal cell death measured by propidium iodide 
incorporation (Silva et al., 2003; Xapelli et al., 2007; Xapelli et al., 2008). However, the 
contribution of individual NPY receptor activation depends on the subregion analysed. In 
neocortical and hippocampal neuronal cultures, the application of NPY before or after kainate 
exposure was able to attenuate neurotoxicity assessed by lactate dehydrogenase efflux and 
caspase-3 activity (Domin et al., 2006). In agreement with this result, Y1 or Y2 receptor 
activation, 30 min after the excitotoxic insult, prevented kainate-induced cell death in 
organotypic hippocampal slice cultures (Xapelli et al., 2007), and NPY applied 6 h after kainate 
treatment decreased cell death in cortical and hippocampal neuronal cultures (Smialowska et 
al., 2009). When NPY, Y2 or Y5 receptor agonist was injected into the hippocampus it was also 
able to reduce the extent of kainate-induced cell death (Smialowska et al., 2003; Smialowska 
et al., 2009). Similarly, NPY, or Y2 or Y5 receptor agonists infused icv reduced kainate-induced 
hippocampal cell death (Wu and Li, 2005). The modulation of hippocampal synaptic 
transmission by NPY system has long been studied (Colmers, 1990; Nadler et al., 2007; Sperk 
et al., 2007). Accordingly, the protective effect of NPY observed in hippocampus is in 
agreement with studies suggesting NPY as an endogenous antiepileptic peptide, and targeting 
NPY system as an antiepileptic strategy by reducing glutamate release and excitability (Vezzani 
and Sperk, 2004; Woldbye and Kokaia, 2004; Silva et al., 2005). 
In various models of neurodegenerative diseases, NPY system is affected by the 
disease (Beal et al., 1986; Minthon et al., 1990; Cannizzaro et al., 2003). This evidence, 
together with the accumulating findings showing protective actions exerted by exogenous 
NPY or NPY receptor agonist application in animal models of neurodegenerative diseases such 
as ParkiŶsoŶ’s disease (Fig. 1.10) (Decressac et al., 2012), and Alzheiŵer’s disease (Rose et al., 
2009; Croce et al., 2011; Croce et al., 2012) indicates that NPY system may respond to neuronal 
injury in order to counteract the progressive neuronal loss (Decressac and Barker, 2012). For 
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example, the icv injection of NPY increases striatal dopamine release (Kerkerian-Le Goff et al., 
1992) and protects dopaminergic neurons, an effect mediated by Y2 receptor activation and 
ERK1/2 and protein kinase B (Akt) pathways (Decressac et al., 2012). 
In the retina, NPY also exerts neuroprotective actions. In primary rat retinal cell 
cultures, NPY pre-treatment inhibited both 3,4-methylenedioxy-N-methylamphetamine 
(MDMA)- and glutamate-induced increased cell death (Alvaro et al., 2008b; Santos-Carvalho 
et al., 2013b). Moreover, in an animal model of excitotoxicity-induced retinal injury by using 
intravitreal injection of glutamate, NPY prevented the injury-induced increase in cell death 
and RGC loss (Santos-Carvalho et al., 2013b). 
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Figure 1.10. Examples of possible neuroprotective effects of NPY in the diseased brain. In the 
striatum, NPY is present in GABAergic neurons that receive inputs from cortical glutamatergic and 
nigral dopaminergic neurons. NPY inhibits glutamate release, thus reducing excitotoxicity in 
ParkiŶsoŶ’s disease. NPY ability to inhibit glial reactivity has been also reported (Ferreira et al., 
2010; Ferreira et al., 2011). NPY has a pro-neurogenic effect on SVZ neural stem cells (Agasse et al., 
2008), and by recruiting the endogenous pool of progenitors NPY might promote the self-repair 
capacity of the adult brain. SVZ, subventricular zone; DA, dopamine; Akt, protein kinase B; DARPP, 
dopamine and cAMP-regulated phosphoprotein (Decressac and Barker, 2012). 
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1.3 – Sildenafil 
 
 
1.3.1 – Mechanism of action 
 
Sildenafil is an orally active inhibitor of PDE type 5 (Fig. 1.11). Sildenafil was initially 
manufactured by Pfizer, as ViagraTM, and used for the treatment of male erectile dysfunction 
(Boolell et al., 1996). 
 
Figure 1.11. Structure of sildenafil citrate. (Salonia et al., 2003). 
 
Since its launch in 1998 sildenafil has been distributed worldwide (Salonia et al., 2003), 
and it has also been used for the treatment of pulmonary arterial hypertension under the 
trade name RevatioTM (Montani et al., 2013). Recommended doses for the treatment of 
erectile dysfunction are 25, 50, and 100 mg to be administered 1 h before sexual activity 
(Salonia et al., 2003), whereas for pulmonary arterial hypertension is usually up to 20 mg three 
times a day (Montani et al., 2013). Concerning erectile dysfunction, sildenafil enhances the 
relaxant effect of NO on the penile corpus cavernosum by inhibiting PDE5 which is responsible 
for degradation of cGMP in this tissue (Fig. 1.12). When sexual stimulation causes local release 
of NO, inhibition of PDE5 by sildenafil increases cGMP concentration causing smooth muscle 
relaxation and subsequent increase in blood flow. Smooth muscle relaxation is partly 
mediated by protein kinase G (PKG) activation leading to a decrease in intracellular Ca2+ levels. 
A similar mechanism is responsible for pulmonary arterial vasodilatation (Ghofrani et al., 
2006).  
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Figure 1.12. Mechanism of action of sildenafil. The figure shows the pathway mediating relaxation 
of vascular smooth muscle and penile erection (only upon sexual stimulation) and pulmonary 
vasodilatation (continuously). Local release of NO from cavernous nerve or endothelial cells 
regulates positively the concentration of cGMP which is then reduced by PDE5. The inhibition of 
PDE5 by sildenafil results in increased cGMP concentration causing smooth muscle relaxation and 
subsequent increase in blood flow. Smooth muscle relaxation is partly mediated by protein kinase 
G activation leading to a decrease in [Ca2+]i. PDE5, phosphodiesterase 5; cGMP, cyclic guanosine 
monophosphate; GMP, guanosine ϱ’-monophosphate; GTP, guanosine ϱ’-triphosphate; NO, nitric 
oxide (Ghofrani et al., 2006). 
 
 
1.3.2 – Ocular side effects 
 
Patients with erectile dysfunction have experienced transient and mild impairments of 
colour discrimination, which are occur at the peak of the drug action (Laties and Zrenner, 
2002). Moreover, sildenafil was found to decrease visual performance, particularly the 
temporal response, in S-cone isolating conditions (Stockman et al., 2007), and, in rare cases, 
transient blindness was reported (Montastruc et al., 2006). It has also been suggested that 
sildenafil might be a possible, but not yet certain, cause of anterior ischaemic optic 
neuropathy (Carter, 2007). However, other studies reported no visual toxic effects in both 
human patients and laboratory animals even after long periods of drug daily use (Vatansever 
et al., 2003; Cordell et al., 2009; Zoumalan et al., 2009). Nonetheless, serious ocular adverse 
effects occur in some patients after sildenafil use. Case reports included cases of central retinal 
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vein occlusion, cilio-retinal artery occlusion, acute angle closure glaucoma and optic atrophy 
(Azzouni and Abu samra, 2011). 
Electroretinogram (ERG) recordings showed decreases in both a- and b-wave 
amplitudes in sildenafil-treated patients (Vobig et al., 1999) or inversely, an increase in the 
scotopic ERG responses, but a decrease in the photopic response (Luu et al., 2001). Other 
studies reported increase in Naka-Rushton equation Vmax, suggesting higher rod response 
after 50 or 100 mg sildenafil ingestion (Gabrieli et al., 2001; Gabrieli et al., 2003). More 
consistently, among all human studies, sildenafil enlarged the latencies of the different 
responses (Luu et al., 2001; Jagle et al., 2004; Jagle et al., 2005). Ex vivo experiments showed 
also contradictory results. Sildenafil has been shown to increase ERG amplitudes in the rat 
retina (Barabas et al., 2003), whereas it decreases ERG amplitudes in bovine and human 
retinas, while increasing the latencies (Luke et al., 2005; Luke et al., 2007). 
Although not completely elucidated, the effects of sildenafil on retinal function might 
result from the inhibition of PDE5, expressed in retinal cells, including human RGCs (Foresta 
et al., 2008). However, apart from the inhibition of PDE5, other PDEs may be inhibited by 
sildenafil, namely PDE6, which controls the phototransduction cascade in photoreceptors 
(Beavo, 1995; Lamb, 2013). For detailed description of phototransduction cascade see section 
1.1.2. Sildenafil appears almost equally potent on cone PDE6 as on PDE5, whereas it seems 
slightly less potent on rod PDE6 (Ballard et al., 1998; Zhang et al., 2005). PDE4 is also expressed 
in RGCs, bipolar cells, cholinergic amacrine cells and rods (Whitaker and Cooper, 2009), 
whereas PDE1 and PDE9 were described so far in bipolar cells (Dhingra et al., 2008). 
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1.4 – Objectives 
 
NPY is widely distributed in central and peripheral nervous system and present 
neuromodulatory and neuroprotective properties (Xapelli et al., 2006). In the retina, NPY 
presence has been demonstrated in different species, though NPY receptor localization has 
been scarcely investigated (Santos-Carvalho et al., 2014). We and others have presented 
evidence suggesting a neuromodulatory role of NPY in the retina. NPY application regulates 
neurotransmitter release in rabbit and chicken retinas (Bruun and Ehinger, 1993). Also, NPY 
attenuates depolarization-induced increase in [Ca2+]i in primary retinal cell cultures (Alvaro et 
al., 2009), and decreases depolarization-dependent Ca2+ influx into bipolar cells (D'Angelo and 
Brecha, 2004). Moreover, in retinas with selective ablation of NPY-expressing amacrine cells, 
it was reported an alteration in the receptive field properties of RGCs, though a direct effect 
of NPY was not demonstrated (Sinclair et al., 2004). These results suggest that NPY-induced 
modulation of visual circuitry might result in changes of RGC spiking activity. Therefore, in the 
first part of the present study, we intended to further investigate the presence of NPY and 
NPY receptors in the retina at mRNA and protein level, and also, we intended to study the NPY 
modulatory potential at RGC level using purified RGC cultures and ex vivo retinal preparations. 
In purified RGC cultures, we have evaluated the effect of exogenous application of NPY in 
[Ca2+]i changes triggered by glutamate, and in ex vivo retinal preparations we have assessed 
the light- or NMDA-stimulated RGC spiking activity. 
Previous work from our laboratory have shown that NPY exerts a neuroprotective 
action against different toxic insults. In primary rat retinal cell cultures NPY pre-treatment 
prevented increased cell death induced by both MDMA and glutamate (Alvaro et al., 2008b; 
Santos-Carvalho et al., 2013b). In an animal model of excitotoxicity-induced retinal injury, 
intravitreal administration of NPY inhibited both the increase in cell death, and RGC loss 
induced by glutamate (Santos-Carvalho et al., 2013b). Retinal degenerative diseases affecting 
RGCs, in particular, glaucoma which is the major cause of irreversible blindness worldwide 
(Quigley and Broman, 2006), remain with no effective treatment able to halt the progression 
of RGC death. Therefore, we also evaluated the potential neuroprotective effects of NPY 
application against RGC death in an in vitro model of excitotoxicty and in an animal model of 
retinal I-R injury. 
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Sildenafil is a PDE type 5 inhibitor widely used for treatment of erectile dysfunction 
(Salonia et al., 2003), and also for pulmonary arterial hypertension (Montani et al., 2013). 
Patients with erectile dysfunction have experienced transient and mild impairments of colour 
discrimination, which are occurring at the peak of the drug action (Laties and Zrenner, 2002).  
Moreover, sildenafil was found to decrease visual performance, particularly temporal 
response, in S-cone isolating conditions (Stockman et al., 2007), and, in rare cases, transient 
blindness was reported (Montastruc et al., 2006). In order to understand the effects of 
sildenafil on retinal function different electrophysiological studies have been performed. 
However, these studies have yielded contradictory results. In vivo ERG recordings showed 
decreases in both a- and b-wave amplitudes in sildenafil-treated patients (Vobig et al., 1999), 
or inversely, an increase in the scotopic ERG responses, but a decrease in the photopic 
response (Luu et al., 2001). Ex vivo experiments have also shown some contradictory results. 
Sildenafil has been shown to increase ERG amplitudes in the rat retina (Barabas et al., 2003), 
whereas it decreases ERG amplitudes in bovine and human retinas, while increasing the 
latencies (Luke et al., 2005; Luke et al., 2007). To our knowledge, no studies so far have 
evaluated the effects of sildenafil, directly on RGC spiking activity, which forms the retinal 
output signal to the brain. Therefore, to further elucidate this issue, in the second part of the 
present study, we intended to investigate, using a MEA and ex vivo retinal preparations, the 
effect of different concentrations of sildenafil on principal characteristics of light-induced RGC 
responses (magnitude and latency) and the spontaneous RGC spiking activity. 
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2.1 – Animals 
 
Wistar rats, 8-10 weeks old, were obtained from Charles River, France. Long Evans rats, 
8-10 weeks old, were obtained from Charles River for retinal ganglion cell (RGC) purification 
experiments and from Janvier Labs, Le Genest Saint Isle, France, for multi-electrode array 
(MEA) experiments. Animals were housed in a temperature- and humidity-controlled 
environment and were provided with standard rodent diet and water ad libitum while kept 
on a 12 h light/12 h dark cycle. All procedures involving the animals were in agreement with 
the guidelines on the ethical use of animals from the European Community Council Directive 
2010/63/EU, transposed to Portuguese laǁ iŶ ͞DeĐreto-Lei nº 113/2013͟. 
 
 
2.2 – Drugs and reagents 
 
NPY and NPY receptor agonists and antagonists, as well as glutamate (L-glutamic acid), 
N-methyl-D-aspartic acid (NMDA), glycine, and sildenafil were exogenously applied to retinal 
cells and are listed in Table 1. NPY and NPY receptor agonist stock solutions (100-1000x) were 
dissolved in 0.0001% Tween 20 (Merck Millipore, Billerica, MA, USA) to reduce adsorption to 
plastic. For the remaining reagents, the manufacturer is indicated throughout the text. When 
not indicated, the reagent was obtained from Sigma-Aldrich, St. Louis, MO, USA. 
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Table 1. List of drugs used in the various experiments. 
NMDAR, NMDA receptor 
aBachem, Bubendorf, Switzerland 
Tocris Bioscience, Bristol, UK 
Sigma-Aldrich, St. Louis, MO, USA 
Calbiochem, Merck Millipore, Billerica, MA, USA 
b(Gly1, Ser3,22, Gln4,34, Thr6, Arg19, Tyr21, Ala23,31,Aib32)-pancreatic polypeptide 
 
 
2.3 – Retinal ganglion cell purification 
 
Purified RGCs were obtained from the retinas of either 3-4 days old pups or 8-10 weeks 
old Wistar or Long Evans rats by sequential immunopanning (Fig. 2.1), as previously described 
(Barres et al., 1988), with some modifications. This procedure is based on the expression of 
cell surface protein Thy 1 on RGCs, which is used to isolate RGCs in an immunopanning step. 
Other cell types, non-RGCs, namely macrophages and endothelial cells that also adhere to 
anti-Thy-1 coated plates (Barres et al., 1988), are removed in a preceding step with anti-
macrophage serum. Next, the entire procedure is detailed. Rats were killed by decapitation or 
Drug Purpose Concentration
Catalog 
number
Manufacturera
NPY Y1/Y2/Y4/Y5 agonist 1-10 µM H-6375 Bachem
(Leu31, Pro34)-NPY Y1/Y5 agonist 1 µM H-3306 Bachem
NPY (13-36) Y2 agonist 0.3-1 µM H-3324 Bachem
(Gly1, …Aiď32)-PPb Y5 agonist 1 µM H-5088 Bachem
BIBP 3226 Y1 antagonist 1 µM 2707 Tocris
BIBO 3304 Y1 antagonist 10 µM 2412 Tocris
BIIE 0246 Y2 antagonist 1-10 µM 1700 Tocris
L-152,804 Y5 antagonist 1-100 µM 1382 Tocris
NMDA NMDAR agonist 30-300 µM M3262 Sigma-Aldrich
L-Glutamic acid
Agonist of all 
glutamate receptors
1-1000 µM G1251 Sigma-Aldrich
Glycine
Co-agonist of 
NMDAR
10 µM 104201 Calbiochem
Sildenafil PDE5 inhibitor 0.3-30 µM PZ0003 Sigma-Aldrich
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cervical dislocation, the eyes enucleated and the retinas dissected in ice cold sterile Dulbecco's 
Modified Eagle Medium (DMEM; Gibco, Life Technologies, Grand Island, NY, USA) 
supplemented with 5% D-glucose and 44 mM NaHCO3. Retinas were incubated for 30 min at 
ϯϳ °C iŶ Earl’s BalaŶĐed “alt “olutioŶ ;EB““; in mM: 1.8 CaCl2, 0.8 MgSO4, 5.3 KCl, 26 NaHCO3, 
117 NaCl, 1 NaH2PO4, 5.6 D-glucose, pH 7.4) containing 16.5 U/ml papain (Worthington 
Biochemical, Lakewood, NJ, USA), 1.65 mM L-cysteine, and 124 U/ml deoxyribonuclease I 
(DNase I), to allow tissue digestion. The cell suspension was gently triturated in an enzyme 
inhibitor solution containing 1.5 mg/ml ovomucoid (Roche, Basel, Switzerland), 1.5 mg/ml 
bovine albumin serum (BSA) and 124 U/ml DNase I in EBSS. The retinal tissue was allowed to 
settle for 1-2 min. Then, ovomucoid solution was discarded and retinal tissue further 
triturated in a solution containing 1.5 mg/ml ovomucoid (Roche), 1.5 mg/ml BSA, 124 U/ml 
DNase I and 1:125 (v:v) rabbit anti-rat macrophage antiserum (Accurate Chemical, Westbury, 
NY, USA), to yield a single cell suspension, and incubated for 10 minutes at RT. After 
centrifugation for 11 min at 190 g at RT, the supernatant was discarded and cells were 
resuspended in EBSS containing 10 mg/ml ovomucoid (Roche) and 10 mg/ml BSA and then 
centrifuged for 10 min at 190 g at RT. The supernatant was discarded and cells resuspended 
iŶ DulďeĐĐo’s Phosphate Buffered “aliŶe ;DPB“; in mM: 0.9 CaCl2, 0.5 MgCl2, 2.7 KCl, 1.47 
KH2PO4, 138 NaCl, 8 Na2HPO4, 0.33 sodium pyruvate (Gibco), 5.6 D-glucose, pH 7.4) containing 
0.2 mg/ml BSA and 5 µg/ml insulin. Cell suspension was plated in a 150 mm Petri dish coated 
with 5.3 µg/ml goat anti-rabbit IgG (H+L) antibody (Rockland Immunochemicals, Gilbertsville, 
PA, USA). After 30 min at RT, non-adherent cells were removed to a second 150 mm Petri dish 
coated similarly.  After 30 min at RT, non-adherent cells were removed to a 100 mm dish 
coated with 6.7 μg/ml goat anti-mouse IgM antibody (Rockland Immunochemicals) and mouse 
anti-rat Thy1.1 hybridoma supernatant of T11D7e cell line (TIB-103, ATCC, Manassas, VA, 
USA). After 30 min, the non-adherent cells were washed out with Ca2+- and Mg2+-free DPBS 
(in mM: 138 NaCl, 2.7 KCl, 8 Na2HPO4, 1.47 KH2PO4, pH 7.4), and the adherent RGCs were 
detached with a 0.125% trypsin solution in Ca2+- and Mg2+-free EBSS (in mM: 116 NaCl, 5.3 
KCl, 1 NaH2PO4, 5.6 D-glucose, 26 NaHCO3, pH 7.4). Trypsinization was stopped with 30% FBS 
(Gibco) in Neurobasal-A (Gibco), and the RGCs were detached. The cell suspension was 
centrifuged for 10 min at 190 g, at RT, and the supernatant was discarded. 
For cell culturing, RGCs were resuspended in Neurobasal-A (Gibco) medium containing 
1x B27 supplement (Gibco), 5 μg/ml insulin, 1mM sodium pyruvate (Gibco), 1x 
Sato/Bottenstein supplement which includes 100 µg/ml transferrin, 100 µg/ml BSA, 16 µg/ml 
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putrescine, 62 ng/ml progesterone, and 40 ng/ml sodium selenite, 40 ng/ml triiodo-L-
thyronine, 2 mM L-glutamine, 5 mg/ml N-acetylcysteine, 100 µM inosine, 20 ng/ml ciliary 
neurotrophic factor (Peprotech, Rocky Hill, NJ, USA), 25 ng/ml brain-derived neurotrophic 
factor (Peprotech), 5 µM forskolin, 10 ng/ml basic fibroblast growth factor (Gibco) and 50 
µg/ml gentamicin (Gibco), and were plated at a density of 460 cells/mm2 on 12 mm glass 
coverslips coated with 10 μg/ml poly-D-lysine and 10 µg/ml laminin. Cells were cultured for 
16 to 48 h at 37 °C in a humidified environment of 5% CO2. For RNA extraction, the cell pellet 
was lysed in TRIzolTM reagent, as further described below. 
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Figure 2.1. RGC purification by sequential immunopanning. Eyes from Wistar or Long Evans rats 
(1) were enucleated (2) and the retinas dissected (3). Retinas were incubated with papain (4) to 
allow tissue digestion. Retinas were then gently triturated (5) and the cell suspension incubated 
with rabbit anti-rat macrophage antiserum (6). After further dissociation and centrifugation to 
remove papain, the obtained cell suspension (7) was plated in a Petri dish coated with anti-rabbit 
IgG to remove non-RGCs expressing Thy1 (8; blue cells). Then non-adherent cells were plated in a 
Petri dish coated with anti-rat Thy1.1 hybridoma supernatant to isolate RGCs (9; yellow cells). Non-
adherent cells were discarded and the adherent RGCs were incubated with trypsin (10). RGCs were 
then detached (11) and cultured up to 48 h (12). Adapted from (Winzeler and Wang, 2013). 
 
 
2.4 – Culture of retinal explants 
 
Wistar rats (8-10 weeks old) were killed by cervical dislocation. Retinas were dissected 
in Ca2+- and Mg2+-free HaŶk’s BalaŶĐed “alt “olutioŶ (HBSS, in mM: 5.4 KCl, 0.44 KH2PO4, 137 
NaCl, 4.2 NaHCO3, 0.34 Na2HPO4, 5.6 D-glucose, 10 HEPES, 1 sodium pyruvate, pH 7.4) and 
flat-mounted onto 30 mm diameter culture plate inserts with a 0.4 μm pore size (Millicell, 
Merck Millipore, Billerica, MA, USA), with the GCL facing upward (Fig. 2.2). The retinal explants 
were cultured in six-well plates in Neurobasal-A (Gibco, Life Technologies, Grand Island, NY, 
USA) medium containing 1x B27 supplement (Gibco), 2 mM L-glutamine and 50 μg/ml 
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4 65
7 98
10 1211
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gentamicin (Gibco), and maintained for 4 days in vitro (DIV) in a humidified environment at 37 
°C and 5% CO2. 
 
Figure 2.2. Cultured retinal explant. Example of a retinal explant on a culture insert with the GCL 
facing upward. 
 
 
2.5 – Reverse-transcription polymerase chain reaction (RT-PCR) 
 
Total RNA was isolated from RGCs using TRIzolTM reagent (Ambion, Life Technologies, 
Grand Island, NY, USA). Subsequently, cDNA first strand synthesis was performed from 2 μg 
DNase-treated RNA using random primers and SuperScript II Reverse Transcriptase 
(Invitrogen, Life Technologies). The resulting cDNA (0.5 μl) was used for amplification of 
respective targets with AmpliTaq Gold DNA polymerase (Applied Biosystems, Life 
Technologies), 200 nM of primer and 2 mM MgCl2, in a Veriti thermal cycler (Applied 
Biosystems). Reactions were performed as follows: denaturation for 3 min at 95 °C; 40 cycles, 
each consisting of 95 °C for 30 sec, annealing temperature for 30 sec, and 72 °C for 30 sec; and 
final extension at 72 °C for 5 min. The primers used are indicated in Table 2. PCR products 
were separated on a 1.5% agarose gel. β-actin was used as an internal control. The gel images 
were digitally acquired in a Gel/ChemiDoc (Bio-Rad Laboratories, Hercules, CA, USA) and the 
level of gene transcription was evaluated and categorized as detected or not detected. 
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Table 2. Primers used for RT-PCR. 
bp, base pairs 
 
 
2.6 – Immunofluorescence labelling 
 
2.6.1 – Immunocytochemistry in purified retinal ganglion cells 
Purified RGCs were fixed with 4% paraformaldehyde (PFA) for 20 min at RT in 
phosphate buffer saline (PBS; in mM: 137 NaCl, 2.7 KCl, 1.8 KH2PO4, 10 Na2HPO4, pH 7.4), 
washed three times in PBS and permeabilized with 1% Triton X-100 in PBS for 5 min at RT. 
After washing three times in PBS, the unspecific binding was prevented by incubating cells in 
a 3% BSA and 0.2% Tween 20 (Merck Millipore, Billerica, MA, USA) blocking solution, in PBS 
for 60 min at RT. Then, cells were incubated with primary antibodies (Table 3) diluted in 
blocking solution for 90 min at RT as follows: rabbit anti-NPY (1:1000), anti-Y1 (1:500), anti-Y2 
(1:500), anti-Y4 (1:25), anti-Y5 (1:250), or anti-Brn3a (1:25). After washing three times in PBS, 
cells were incubated with the secondary antibodies diluted in blocking solution for 60 min at 
RT as follows: Alexa Fluor (AF) 568 anti-mouse (1:200), AF 488 anti-rabbit (1:200), or AF 488 
anti-sheep (1:200). After washing three times in PBS, the nuclei were stained with 2.5 µg/ml 
Target
Forǁard Primer ;5’-3’Ϳ
Reǀerse Primer ;5’-3’Ϳ
Annealing 
Temperature
Product Size
NPY
AGAGATCCAGCCCTGAGACA
TTTCATTTCCCATCACCACA
57 ºC 110 bp
Y1 receptor
ACGTTCGCTTGAAAAGGAGA
CATGACGTTGATTCGTTTGG
57 ºC 89 bp
Y2 receptor
CAGTTTTGTGCCATTTGGTG
AGGAAGCTGATTTGCTTGGA
60 ºC 142 bp
Y4 receptor
ATCTCATGGCCTCCCTTTCT
TCTCAACGCTGTAGGTGGTG
57 ºC 141 bp
Y5 receptor
ATACAGCTGCTGCTCGGAAT
GATTGCCCATAAAGCCAAGA
57 ºC 126 bp
Brn3a
CCCTGAGCACAAGTACCCGTCGCTGC
CCGGCTTGAAAGGATGGCTCTTGCCC
60 ºC 184 bp
GFAP
TGGTATCGGTCCAAGTTTGCA
TGGCGGCGATAGTCATTAGC
60 ºC 98 bp
CD11b
GATGCTTACTTGGGTTATGCTT
CGAGGTGCCCCTAAAACCA
60 ºC 74 bp
β-actin CTAAGGCCAACCGTGAAAAG
ATCACAATGCCGTGGTACG
60 ºC 124 bp
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DAPI (Molecular Probes, Life Technologies, Grand Island, NY, USA) for 10 min at RT. After 
washing three times in PBS, the coverslips were mounted on glass slides using GlycergelTM 
mounting medium (Dako, Agilent Technologies, Santa Clara, CA, USA). Images were acquired 
in a laser scanning confocal microscope LSM 710 (Zeiss, Oberkochen, Germany). 
  
Materials & Methods 
 
51 
 
Table 3. List of antibodies used for immunofluorescence labelling. 
AF, Alexa Fluor 
aSigma-Aldrich, St. Louis, MO, USA 
AbD Serotec, Bio-Rad Laboratories, Hercules, CA, USA 
Alomone Labs, Jerusalem, Israel 
Merck Millipore, Billerica, MA, USA 
Lab Vision, Thermo Fisher Scientific, Walthman, MA, USA 
Molecular Probes, Life Technologies, Grand Island, NY, USA 
 
2.6.2 – Immunohistochemistry in retinal sections 
Adult Wistar rats were transcardially perfused with 250 ml PBS followed by 250 ml 4% 
PFA at RT, under deep anaesthesia with 90 mg/kg (ip) ketamine (ImalgeneTM, Merial, Porto 
Salvo, Portugal) and 10 mg/kg (ip) xylazine (RompunTM, Bayer, Leverkusen, Germany). Then, 
the eyes were enucleated and the lens were removed. The eye cup was further fixed for 60 
min in PFA. After washing in PBS, the tissue was transferred sequentially to 15% and 30% (w/v) 
sucrose in PBS for at least 120 min each. The eye cup was embedded in a mixture 1:1 of 30% 
sucrose and cryomatrix embedding resin (Thermo Fisher Scientific, Walthman, MA, USA), and 
stored at -80 °C. Retinal sections, 10 μm thickness, were obtained in a cryostat and collected 
on SuperFrost Plus glass slides (Menzel-Glaser, Thermo Fisher Scientific) and stored at -20 °C. 
Retinal sections air dried for at least 45 min at RT and were fixed with acetone for 10 min at -
Antibody Dilution Catalog Number Manufacturera
Rabbit anti-NPY 1:1000 - 1:10000 N9528 Sigma-Aldrich
Sheep anti-Y1 receptor 1:200 - 1:500 6732-0150 AbD Serotec
Rabbit anti-Y2 receptor 1:500 - 1:2000 ANR-022 Alomone Labs
Rabbit anti-Y4 receptor 1:25 - 1:200 ANR-024 Alomone Labs
Rabbit anti-Y5 receptor 1:250 - 1:2000 ANR-025 Alomone Labs
Mouse anti-Brn3a 1:25 - 1:500 MAB 1585 Merk Millipore
Mouse anti-Vimentin 1:500 MS129P1 Lab Vision
AF 568 goat anti-rabbit 1:500 A-11011 Molecular Probes
AF 488 goat anti-rabbit 1:200 A-11008 Molecular Probes
AF 568 goat anti-mouse 1:200 - 1:500 A-11004 Molecular Probes
AF 488 goat anti-mouse 1:500 A-11001 Molecular Probes
AF 488 donkey anti-sheep 1:200 - 1:500 A-11015 Molecular Probes
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20 °C. In the case of Y2, Y4, and Y5 receptors, the fixation with acetone was replaced by an 
antigen retrieval step with 10 mM sodium citrate (Panreac, Barcelona, Spain) and 0.05% 
Tween 20 (Merck Millipore), pH 6, for 30 min at 95 °C. The sections were then washed two 
times in PBS and permeabilized in 0.25% Triton X-100 in PBS for 30 min at RT. Sections were 
blocked in 1% BSA and 10% goat serum (donkey serum in the case of Y1) in PBS for 30 min at 
RT. Sections were incubated overnight at 4 °C with primary antibodies (Table 3) diluted in 1% 
BSA in PBS: anti-NPY (1:10000), anti-Y1 (1:200), anti-Y2 (1:2000), anti-Y4 (1:200), anti-Y5 
(1:2000), anti-Brn3a (1:500), or anti-Vimentin (1:500). After washing three times in PBS for a 
total of 30 min, sections were incubated for 60 min at RT with the corresponding secondary 
antibodies diluted in 1% BSA in PBS: AF 488 anti-mouse (1:500), AF 568 anti-mouse (1:500), 
AF 568 anti-rabbit (1:500), or AF 488 anti-sheep (1:500). After washing three times in PBS for 
a total of 30 min, the nuclei were stained with DAPI (2.5 µg/ml, Molecular Probes) in PBS for 
10 min at RT and the sections were coverslipped using GlycergelTM mounting medium (Dako). 
Images were acquired in a laser scanning confocal microscope LSM 710 (Zeiss). 
 
2.6.3 – Immunohistochemistry in retinal explants 
Retinal explants were washed two times with PBS and fixed in 100% ethanol (Merck 
Millipore) at -20 °C for 10 min. After washing the explants three times in PBS, unspecific 
binding was prevented by incubating explants in a 10% goat serum, 1% BSA, and 0.1% Tween 
20 (Merck Millipore) in PBS blocking solution for 60 min at RT. Retinal explants were then 
incubated with anti-Brna3a antibody (Table 3) diluted (1:500) in blocking solution for 3 days 
at 4 °C. After washing again the explants more than six times in PBS for a total of 24 h, explants 
were incubated with the secondary antibody AF 568 anti-mouse (1:200). Then, after washing 
explants more than six times in PBS for a total of 24 h, explants were coverslipped using 
GlycergelTM mounting medium (Dako). Images were acquired in a laser scanning confocal 
microscope LSM 710 (Zeiss). 
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2.7 – TdT-mediated dUTP nick-end labelling (TUNEL) assay  
 
2.7.1 – TUNEL in retinal slices 
The TUNEL assay measures the fragmented DNA of apoptotic cells by incorporating 
fluorescein labelled dUTPs at 3'-OH DNA ends using terminal deoxynucleotidyl transferase 
(TdT). The TdT enzyme forms a polymeric tail allowing visualization in histological sections 
(Gavrieli et al., 1992). TUNEL assays was performed following the manufacturer’s instructions 
(Catalog number: G3250; Promega, Madison, WI, USA). After Brn3a labelling procedure as 
above mentioned, retinal sections were washed three times in PBS for a total of 30 min and 
then permeabilized with 20 μg/ml proteinase K in PBS for 10 min at RT. After washing in PBS 
for 5 min, the sections were incubated with equilibration buffer (in mM: 200 potassium 
cacodylate, 25 Tris, 0.2 dithiothreitol, 2.5 CoCl2, and 0.25 mg/ml BSA, pH 6.6) for 10 min at RT. 
Next, sections were incubated with 600 U/ml recombinant TdT enzyme and nucleotide mix 
containing 5 µM fluorescein-12-dUTPs, 10 µM dATP, and 0.1 mM EDTA, diluted in 
equilibration buffer at 37 °C for 60 min. The reaction was stopped by immersing the slides in 
saline-citrate buffer (in mM: 300 NaCl, 30 sodium citrate, pH 7.0) for 15 min at RT. After 
washing three times in PBS, the nuclei were stained with DAPI (2.5 μg/ml, Molecular Probes, 
Life Technologies, Grand Island, NY, USA) for 10 min at RT. After washing three times in PBS 
sections were mounted with GlycergelTM mounting medium (Dako, Agilent Technologies, 
Santa Clara, CA, USA). Images of retinal sections were acquired in a fluorescence microscope 
(DM IRE2, Leica, Wetzlar, Germany). The Brn3a- and TUNEL-positive cells were counted and 
results were expressed per mm of GCL length. 
 
2.7.2 – TUNEL in retinal explants 
Retinal explants were fixed in 4% PFA in PBS for 15 min at RT and permeabilized with 
20 μg/ml proteinase K in PBS for 15 min at RT. After washing in PBS, retinal explants were fixed 
in 4% PFA in PBS for 5 min, washed in PBS, and incubated in equilibration buffer for 10 min at 
RT. Then, retinal explants were incubated with 600 U/ml recombinant TdT enzyme and 
nucleotide mix containing 5 µM fluorescein-12-dUTPs, 10 µM dATP, and 0.1 mM EDTA, diluted 
in equilibration buffer at 37 °C for 60 min. The reaction was stopped by incubating the retinal 
explants in saline-citrate buffer for 15 min at RT. After washing in PBS, the nuclei were stained 
with DAPI (2.5 μg/ml, Molecular Probes) in PBS for 15 min at RT and retinal explants mounted 
CHAPTER 2 
 
54 
 
with GlycergelTM mounting medium (Dako). At least 12 images of GCL per retinal explant (three 
images per each quadrant) were acquired in a laser scanning confocal microscope LSM 710 
(Zeiss, Oberkochen, Germany). 
 
 
2.8 – Propidium iodide incorporation assay 
 
Propidium iodide (PI) binds nucleic acids by intercalating the bases and can be 
visualized under fluorescence microscope, with maximum fluorescence emission at 608 nm 
(red) and maximum excitation at 540 nm (green). PI is only incorporated in dead or dying cells 
with disrupted cell membranes, thus allowing evaluating cells undergoing necrotic or late 
apoptotic cell death. For PI incorporation assay, cultured retinal explants were incubated with 
2 µM PI for 180 min at DIV2 and at DIV4. Images comprising the four quadrants of retinal 
explant were acquired in a fluorescence microscope (DM IRE2, Leica, Wetzlar, Germany). PI-
positive cells were counted at DIV2 before NMDA treatment and at DIV4. The extent of cell 
death was expressed as the ratio between PI-positive cells at DIV4 and DIV2. 
 
 
2.9 – [35S]GTPγS binding in retinal sections 
 
[35S]GTPγS binding assay has been widely used to evaluate the activation of GPCRs 
taking advantage of a radiolabeled non-hydrolyzable GTP analogue - [35S]GTPγS (Harrison and 
Traynor, 2003). Upon activation of the GPCR by an agonist, Gα binds [35S]GTPγS allowing the 
measurement of the amount of radiolabeled GTP bound to the cell membrane (Fig. 2.3). In 
order to evaluate the presence of functional active NPY receptors in the rat retina, we used 8-
10 weeks old Wistar rats. The eyes were enucleated and frozen in dry ice. Retinal slices, 18 µm 
thickness, were obtained in a cryostat, collected onto SuperFrost Plus glass slides (Menzel-
Glaser, Thermo Fisher Scientific, Walthman, MA, USA) and stored at -80 °C until further 
processing. Sections were air dried for 30 min at RT and then rehydrated in assay buffer A (in 
mM: 50 Tris-HCl, 3 MgCl2, 0.2 EGTA, 100 NaCl, pH 7.4) for 10 min at RT. Sections were pre-
incubated in assay buffer B [assay buffer A + 0.2 mM dithiothreitol, 1 µM 1,3-dipropyl-8-
cyclopentylxanthine (DPCPX), 0.5% w/v BSA, and 2 mM GDP] for 15 min at RT to shift all G-
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proteins into the inactive state. Subsequently, incubation of retinal slices was performed in 
assay buffer B + 50 pM [35S]GTPγS (1250 Ci/mmol; PerkinElmer, Waltham, MA, USA) for 60 
min at RT with 1-10 µM NPY. In each experiment, basal binding was determined by incubation 
without NPY receptor ligands but with assay buffer B + 50 pM [35S]GTPγS (1250 Ci/mmol). 
Specificity was confirmed by adding a combination of the NPY receptor antagonists: 10 µM 
BIBO 3304 for Y1; 10 µM BIIE 0246 for Y2; 100 µM L-152,804 for Y5. For antagonistic studies, 
NPY receptor antagonists were also added to the pre-incubation buffer B. Incubation was 
terminated by two washes of 5 min each in ice cold 50 mM Tris-HCl buffer, pH 7.4, followed 
by a final wash in deionised water. Sections were air dried at RT and exposed to Kodak BioMax 
MR autoradiography films (Carestream Health, Rochester, NY, USA) together with 14C-
microscales (Amersham, GE Healthcare, Little Chalfont, UK) for 5 days at -20 °C. The films were 
developed in Kodak GBX developer. Retinal slices in autoradiography films were acquired with 
a digital camera Axiocam ERc5s (Zeiss, Oberkochen, Germany) coupled to a stereo microscope 
Discovery.V8 (Zeiss). The optical densities of retinal slices were measured using ImageJ 
software (http://imagej.nih.gov/ij/) and the values obtained converted to estimated nCi/g 
tissue using 14C-microscales. 
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Figure 2.3. [35S]GTPγS binding to GPCR. Upon activation of the GPCR by an agonist, Gα subunit 
release GDP and binds [35S]GTPγS. From www.perkinelmer.com. 
 
 
2.10 – Ca2+ imaging in purified retinal ganglion cells 
 
Purified RGCs cultured for 1 or 2 DIVs were used to assess the [Ca2+]i using the Ca2+ dye 
Fura-2-acetoxymethyl ester (Fura-2-AM). Fura-2-AM is a membrane permeable ratiometric 
calcium indicator which fluorescence excitation spectrum shifts to shorter wavelengths upon 
binding to Ca2+ (Grynkiewicz et al., 1985). This property allows for measurements of [Ca2+]i 
based on ratio calculation between fluorescence obtained when excited at 340 and 380 nm. 
The AM group enable Fura-2 to cross the cell membrane. Once the dye is taken up into cells 
the AM group is removed by esterases and the dye is trapped inside. Next, the entire 
procedure is detailed. Purified RGC cultures were washed two times in 0.1% free fatty acid 
BSA (Calbiochem, Merck Millipore, Billerica, MA, USA) in Mg2+-free HBSS solution (in mM: 138 
NaCl, 5.3 KCl, 0.34 Na2HPO4, 0.44 KH2PO4, 2.6 CaCl2, 5.6 D-glucose, 15 HEPES, 4.2 NaHCO3, pH 
7.4) at 37 °C. After washing, RGCs were then loaded with 5 µM Fura-2-AM in the presence of 
0.02% Pluronic F-127 (both Molecular Probes, Life Technologies, Grand Island, NY, USA) in 
0.1% free fatty acid BSA in Mg2+-free HBSS for 45 min at 37 °C. After washing two times in 0.1% 
free fatty acid BSA in Mg2+-free HBSS at 37 °C, RGCs were incubated in Mg2+-free HBSS for 15 
min at 37 °C. Under continuous perfusion (2.9 ± 0.1 ml/min) with Mg2+-free HBSS solution, 
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RGCs were exposed to glutamate for 30 sec (Fig. 2.4 A, B), and all glutamate stimuli included 
10 µM glycine, a co-agonist of NMDA glutamate receptor, as previously described (Hartwick 
et al., 2004). RGCs were alternately excited at 340 and 380 nm, with a fluorescence 
microscope Axiovert 200 (Zeiss, Oberkochen, Germany) coupled to a perfusion system. A ratio 
of fluorescence intensity (340 nm / 380 nm), as indicative of [Ca2+]i, was calculated for each 
individual cell by Metafluor software (Molecular Devices, Sunnyvale, CA, USA). The increase 
above basal Fura-2 ratio (340 nm / 380 nm) was quantified for each stimulus as a Delta value 
(Fig. 2.4 C). Fura-2 ratios (R) were converted to [Ca2+]i in separate calibration experiments (Fig. 
2.4 D) using the formula: 
 
[Ca2+]i = [Kd(F0/FS)][R – Rmin)/(Rmax – R)], 
 
with Kd for Fura-2 of 224 nM, and where F0/FS is the ratio of fluorescence intensity at 380 nm 
excitation in calcium-free solution over the intensity in solution with saturated Ca2+ levels. The 
minimum value for the Fura-2 ratio (Rmin) was obtained using Ca2+-free HBSS (in mM: 138 NaCl, 
5.3 KCl, 0.34 Na2HPO4, 0.44 KH2PO4, 5.6 D-glucose, 15 HEPES, 4.2 NaHCO3, 5 EGTA, pH 8.0) and 
1 µM ionomycin, after which the cells were perfused with Mg2+-free HBSS and 1 µM ionomycin 
in order to calculate the maximum value for Fura-2 ratio (Rmax). We obtained basal values for 
[Ca2+]i in purified RGC of 54 ± 6 nM, while upon stimulation with 30 µM glutamate and 10 µM 
glycine [Ca2+]i values increased to 733 ± 59 nM, which are in agreement with previous studies 
(Hartwick et al., 2004; Hartwick et al., 2008). 
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Figure 2.4. Ca2+ imaging in purified retinal ganglion cells. (A) Cultured RGCs are shown. Bright field 
image (a) and pseudocolour representation of Fura-2 ratio on basal condition (b) and after 
stimulation with 30 µM glutamate (c) are shown. (B) Fura-2 ratio trace from a cultured RGC 
illustrating the response of RGCs to increasing concentrations of glutamate (10 - 1000 µM). (C) Fura-
2 ratio traces showing RGC responses to two consecutive 30 µM glutamate stimuli for 30 sec each. 
The increase above basal Fura-2 ratio 340 nm / 380 nm was quantified for each stimulus as a Delta 
value. (D) Representative [Ca2+]i trace from a cultured RGC upon three consecutive stimuli of 30 µM 
glutamate, after conversion of Fura-2 ratio to  is illustrated [Ca2+]i. 
 
 
2.11 – Ex vivo multi-electrode array recordings 
 
 2.11.1 – Stimulation and multi-electrode array recordings 
Recording of extracellular action potentials from RGCs is a useful technique to assess 
the effect of exogenously applied drugs on ex vivo retinas (Meister et al., 1994; Rosolen et al., 
2008). Long Evans rats (8 weeks old) were killed by CO2 inhalation and quick cervical 
disloĐatioŶ uŶder diŵ red light. EǇes ǁere eŶuĐleated aŶd plaĐed iŶ oǆǇgeŶated Aŵes’ 
medium (Sigma-Aldrich) at RT. Square pieces of retina (1-2 mm2) were placed into the 
recording chamber (Fig. 2.5 A), with the GCL facing the MEA60 biochip electrode array. The 
electrode array was composed of 60 titanium nitride electrodes (Fig. 2.5 B), 10 μm diameter 
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each, disposed in an 8×8 layout with 100 μm inter-electrode spacing (Multi Channel Systems, 
GmbH, Reutlingen, Germany). Retinas were held in the centre of the electrode array using a 
piece of polycarbonate membrane covered by a U-shaped platinum ring with a nylon mesh. 
During recording sessions, retinas were continuously perfused with Ames’ ŵediuŵ 
equilibrated with 95% O2 and 5% CO2, pH 7.4, at a rate flow of 1.3 ml/min. Retinas were 
maintained at 34-37 °C through a heating pad of the recording system. In order to obtain 
stable recordings, each session started 60 min after placing the retina in MEA recording 
chamber. 
 
Figure 2.5. MEA recordings from RGCs. (A) Scheme of the MEA recording system illustrating the 
position of the retina in the centre of MEA chamber and the light-emitting diode (LED) used to elicit 
light responses. (B) The MEA60 biochip included a MEA chamber where 60 electrodes are 
positioned in the centre. Note that MEA is built on glass allowing for light stimulation through the 
bottom. (C) Examples of RGC spiking activity over 9 electrodes during a recording session using 
MC_Rack software. When the raw waveform (pink) exceeds the manually adjusted threshold 
(horizontal line) for each electrode it is quantified as en event.  
  
MEA recordings were conducted using MEA60 setup (Multi Channel Systems). The 
analogue extracellular neuronal signals from 60 channels were AC amplified (×1000-1200), 
band-pass filtered (200-3000 Hz), sampled at 20-30 kHz, and saved in PC-compatible computer 
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for subsequent off-line analysis. RGC spiking activity was monitored during recording sessions 
(Fig. 2.5 C) using MC_Rack software (Multi Channel Systems). Light-induced responses were 
evaluated under dark conditions (Fig. 2.6 A). To elicit light responses in the RGCs, white light 
episodes from light-emitting diodes (LEDs) driven by a stimulus generator STG-1008 (Multi 
Channel Systems) were applied. The LEDs were positioned 5 mm below the transparent MEA 
chamber and used to generate full-field stimuli in the photopic range (5.0 cd/m2). Stimulus 
consisted of 10 consecutive stimulus blocks with 5 sec light followed by 10 sec dark each. 
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2.11.2 – Spike sorting and data analysis 
The recordings were subsequently subjected to off-line spike sorting and analysis using 
Spike2 (Cambridge Electronic Design, Cambridge, UK). Waveforms were isolated using a 
combination of template matching algorithm and cluster cutting based on principal 
components of individual waveforms (Fig. 2.6 B). The spontaneous activity was calculated for 
each RGC as spiking rate (Hz). 
 
Figure 2.6. MEA recordings from RGCs. (A) Examples of RGC spiking frequency changes over 16 
electrodes upon repeated light stimulation using MC_Rack software. Frequency of detected events 
is shown (red) for each electrode. Note that we only used MC_Rack for live monitoring of spiking 
activity during recording sessions. (B) The spike activity quantification was performed after off-line 
spike sorting using Spike2 software. In order to isolate individual RGC spiking activity, a combination 
of template matching and cluster cutting based on principal components of individual waveforms 
was used. In this example, blue spikes are taken and green spikes are discarded. 
  
To detect changes in spontaneous activity induced by light, the raster and peri-stimulus 
time histograms (PSTH) were generated from 10 stimulus blocks using 50 msec bin widths (Fig. 
2.7). The onset of ON- and OFF-type RGC responses were defined as an increase in spike 
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number higher than 2SD than the pre-stimulus frequency over at least three consecutive bins. 
The initial burst responses to both light onset (ON-type RGCs, Fig. 2.7 A) and dark onset (OFF-
type RGCs, Fig. 2.7 B) were quantified over a 50 msec bin. The mean spiking rates over 1 and 
5 sec after light onset (ON-type RGCs) or dark onset (OFF-type RGCs) were also quantified. The 
majority of RGC light responses were classified as transient showing an initial burst response 
to light or dark onset followed by a rapid decrease in spiking activity. Latency was defined as 
the time delay between light or dark period onset (ON- or OFF-type RGCs respectively) and 
the RGC light response as defined above, when aligned in raster plots for consecutive light 
stimuli. In addition to light stimulation, in some experiments, 30 µM NMDA was applied for 5 
min to induce increased RGC spiking activity. Under continuous perfusion different drugs were 
bath-applied: 1 µM NPY, 1 µM (Leu31, Pro34)-NPY, 1µM NPY (13-36), 1 µM (Gly1, …Aiď32)-PP, or 
0.3 to 30 µM sildenafil citrate. Effects of each drug and concentrations was assessed in, at 
least, 3 different retinal preparations. 
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Figure 2.7. RGC light response quantification. Examples of peri-stimulus time histograms (PSTHs) 
and raster plots for ON- (A) and OFF-type (B) RGC light responses are shown for five consecutive 
stimulus blocks. White bars indicate duration of light period. Blue horizontal bars indicate the time 
window used for quantification of light stimulus-induced mean spiking rate for ON-type RGCs (A), 
namely initial burst (50 msec), 1 sec, and 5 sec. (B) OFF-type RGC light responses were quantified 
similarly, though the starting point for quantification corresponded to dark onset. Note that the 5 
sec bar was shortened to fit in the figure. Vertical dashed lines indicate the position used for latency 
quantification for ON- (A) and OFF-type (B) RGC light responses, determined in aligned raster plots 
for consecutive light stimuli.  
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2.12 – Intravitreal injections and retinal ischemia-reperfusion injury  
 
Wistar rats were anaesthetized by 2.5% isoflurane (Abbott Laboratories, North 
Chicago, IL, USA) inhalation, using a gas-anaesthetizing system (VetEquip, Pleasanton, CA, 
USA) and the O2 flowmeter adjusted to 1 l/min. Then, 4 mg/ml oxybuprocaine (Laboratórios 
Edol, Linda-a-Velha, Portugal) anaesthetic was applied topically to the eyes and the pupils 
dilated with 10 mg/ml tropicamide (Laboratórios Edol). Intravitreal injection of 5 µl containing 
10 μg NPY or sterile saline solution was performed using a 10 μl Hamilton syringe (Hamilton, 
Reno, NV, USA) with a 30-gauge needle, in both eyes, 120 min before the induction of retinal 
ischemia-reperfusion (I-R). Fusidic acid (10 mg/g, Leo Pharmaceutical, Bellerup, Denmark) 
ointment was applied in the conjunctival sac after the intravitreal injections. 
Retinal I-R injury was induced in one eye by elevating the intraocular pressure (IOP) to 
80 mmHg for 60 min. IOP was measured with a tonometer (Tonolab, Icare, Vantaa, Finland). 
The anterior chamber of one eye was cannulated (Fig. 2.8 A) with a 30-gauge needle 
connected to a reservoir infusing sterile saline solution (Fig. 2.8 B). The contralateral eye was 
taken as the control eye. The IOP was raised by elevating the reservoir to a height of 1.8 m. 
Retinal ischemia was confirmed by whitening of the iris and loss of the red reflex. In order to 
avoid corneal opacity, 2% methocelTM (Dávi II, Barcarena, Portugal) was applied to both eyes. 
After 60 min of ischemia, the needle was withdrawn and the reperfusion was established. 
Fusidic acid ointment (10 mg/g) was applied at the end of the experiment. Animals were killed 
after 24 h of reperfusion. 
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Figure 2.8. I-R injury model. (A) Picture illustrating a cannulated rat eye in the anterior chamber. 
(B) Scheme showing the reservoir (arrow) containing the saline solution and the gas-anaesthetizing 
system. 
 
 
2.13 – Electroretinogram recordings 
 
 Electroretinogram (ERG) recordings  are an effective and non-invasive method to study 
in vivo retinal light responses (Rosolen et al., 2005). In some animals subjected to I-R injury 
(three animals per each experimental group), ERGs were recorded before the onset of I-R 
injury (Baseline) and after 24 h of reperfusion. After dark adaptation for at least 12 h the 
animals were anaesthetized with 90 mg/kg (ip) ketamine (ImalgeneTM, Merial, Porto Salvo, 
Portugal) and 10 mg/kg (ip) xylazine (RompunTM, Bayer, Leverkusen, Germany). Then, 4 mg/ml 
oxybuprocaine (Laboratórios Edol, Linda-a-Velha, Portugal) anaesthetic was applied topically 
to the eyes and the pupils dilated with 10 mg/ml tropicamide (Laboratórios Edol) under dim 
red light illumination. The body temperature was maintained with a heating pad set to 37 °C. 
Using a Ganzfeld stimulator (Fig. 2.9 A), white light flashes (9.49 cd-s/m2) were applied under 
scotopic and photopic conditions (in the latter case, after light adaptation to a white 
background, 25 cd/m2) in order to saturate the rod photoreceptor response. Scotopic ERGs 
result mainly from rod photoreceptor activity, while photopic ERGs result from cone 
photoreceptor activity. ERGs were recorded with a corneal gold wire electrode, a reference 
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electrode at the head, and a ground electrode in the tail of the animal. A band width of 1 - 300 
Hz and sampling rate of 3.4 kHz were used for acquisition (Roland Consult GmbH, Brandenburg 
and der Havel, Germany). The scotopic and photopic ERGs were evaluated (Fig. 2.9 B). The a-
wave allows for evaluation of photoreceptor activity and the amplitude was measured from 
the baseline to the a-wave through (Fig. 2.9 C). The a-wave latency was measured from the 
light stimulus onset to the a-wave through. The b-wave allows for evaluation of bipolar cell 
and amacrine cell activity and the amplitude was measured from the a-wave through to the 
b-wave peak, and the b-wave latency was measured from the light stimulus onset to the b-
wave peak (Fig. 2.9 D). Note that in the photopic ERG no clear a-wave is detected due to the 
low number of cone photoreceptors in rodent retina (Cone, 1964; Bayer et al., 2001). OFF-line 
high frequency cut-off of 50 Hz digital filter was applied to determine b-wave, with the 
RETIport software (Roland Consult GmbH). 
Figure 2.9. ERG recordings. (A) Picture illustrating an ERG recording set up. Note that the animal is 
placed on a heating pad and the head is positioned inside the Ganzfeld stimulator. (B) Examples of 
scotopic and photopic ERG waveforms. (C) Example of an ERG waveform, where the a-wave 
amplitude (a) and latency (at) quantification is indicated. (D) Example of an ERG waveform, where 
the b-wave amplitude (b) and latency (bt) quantification after high frequency cut-off of 50 Hz is 
shown. Vertical line indicates the onset of light stimulus. 
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2.14 – Statistical analysis 
 
Statistical analysis was performed with Prism 5 (GraphPad, La Jolla, CA, USA) using one-
ǁaǇ ANOVA folloǁed ďǇ BoŶferroŶi’s test. WheŶ distribution normality was not possible to 
evaluate, or not achieved, one-way Kruskal-Wallis test ǁas used folloǁed ďǇ DuŶŶ’s test, as 
indicated in figure legends. P values less than 0.05 were taken as significant. All values are 
presented as mean ± SEM. 
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3.1 – Introduction 
 
NPY is widely distributed in central and peripheral nervous system. This peptide 
belongs to a family of highly conserved peptides which also includes PP, and PYY, (Michel et 
al., 1998). During the last three decades NPY has been associated with a multitude of 
physiological functions such as energy homeostasis (Chambers and Woods, 2012), stress 
response (Hirsch and Zukowska, 2012), circadian rhythm (Yannielli and Harrington, 2004), 
bone physiology (Lee and Herzog, 2009), neurogenesis (Malva et al., 2012), and immune 
system regulation (Dimitrijevic and Stanojevic, 2013). NPY, PYY, and PP, all activate seven 
transmembrane G protein-coupled receptors named NPY receptors. These receptors all bind 
to Gi/G0 proteins which results in inhibition of AC. Other signalling pathways are also regulated 
such as Ca2+ channels and GIRK channels, (Sun and Miller, 1999), phospholipase C (Perney and 
Miller, 1989), and phosphoinositide 3-kinase (Rosmaninho-Salgado et al., 2012). In humans, 
only four NPY receptors were cloned and known to be functionally active, Y1, Y2, Y4, and Y5 
(Babilon et al., 2013). These receptors have been regarded as potential therapeutic targets 
since NPY was shown to present anti-epileptic and neuroprotective properties (Xapelli et al., 
2006). Indeed NPY receptor activation has been shown to prevent neuronal cell death induced 
by excitotoxic insult (Silva et al., 2003; Xapelli et al., 2007). 
In the retina, NPY presence has been demonstrated in different species, though NPY 
receptor localization has been scarcely investigated (Santos-Carvalho et al., 2014). 
Nevertheless, previous work from our laboratory have shown that NPY exerts a 
neuroprotective action against different toxic insults. In primary rat retinal cell cultures NPY 
pre-treatment prevented increased cell death induced by both MDMA and glutamate (Alvaro 
et al., 2008b; Santos-Carvalho et al., 2013b). In an animal model of excitotoxicity-induced 
retinal injury, intravitreal administration of NPY inhibited both the increase in cell death, and 
RGC loss induced by glutamate (Santos-Carvalho et al., 2013b). In addition, we and others 
presented evidence suggesting a neuromodulatory role of NPY in the retina. NPY application 
regulates neurotransmitter release in rabbit and chicken retinas (Bruun and Ehinger, 1993). 
Also, NPY attenuates depolarization-induced increase in [Ca2+]i in primary retinal cell cultures 
(Alvaro et al., 2009). Moreover, NPY decreases depolarization-dependent Ca2+ influx into 
bipolar cells via activation of Y2 receptors (D'Angelo and Brecha, 2004), and in retinas with 
selective ablation of NPY-expressing amacrine cells, it was reported an alteration in the 
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receptive field properties of RGCs, though a direct effect of NPY was not demonstrated 
(Sinclair et al., 2004). These results suggest that NPY-induced modulation of visual circuitry 
might result in changes of RGC spiking activity. Therefore, in this study, we intended to 
evaluate NPY modulatory potential at RGC level using a purified RGC culture and an ex vivo 
retinal preparation. In addition, since RGC are lost in retinal degenerative diseases such as 
glaucoma, we also evaluated the neuroprotective potential of NPY against excitotoxic or I-R 
injury. 
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3.2 – Results 
 
 
3.2.1 – Expression of NPY and NPY receptors in retinal ganglion cells 
 
 In order to assess the presence of NPY and NPY receptors (Y1, Y2, Y4, and Y5) in RGCs 
we used a method for RGC isolation by immunopanning. After purification of RGC by this 
method, cells were used for RNA extraction or cultured overnight for immunocytochemistry 
assays. To assess the presence of mRNA for NPY and NPY receptors (Y1, Y2, Y4, and Y5) by RT-
PCR, we used RGCs isolated from the retinas of P3-4 pups and 8 weeks old adult rats of two 
different strains: Wistar and Long Evans (Fig. 3.1). We found that mRNA for both NPY and NPY 
receptors (Y1, Y2, Y4, and Y5) were detected in purified RGCs from both rat strains and ages. 
Brn3a (RGC marker) mRNA was clearly detected while glial fibrillary acidic protein GFAP 
(macroglia cell marker) and Cd11b (microglia cell marker) mRNAs were not detected or barely 
detected indicating high purity of the isolated RGCs. 
We also evaluated the immunoreactivity for NPY and NPY receptors in purified RGCs 
from P3-4 Wistar rats cultured overnight. We found NPY-ir in RGCs with co-localization with 
the RGC marker Brn3a (Fig. 3.2 a). A less intense Y1 receptor-ir was also detected in Brn3a-
positve RGCs (Fig. 3.2 b). Similar to NPY-ir, immunoreactivity for Y2, Y4, and Y5 receptors was 
also detected in RGCs (Fig. 3.2 c-e). In addition, we assessed the localization of NPY and NPY 
receptors in retinal sections of adult Wistar rats. NPY-ir was detected in ramified dendrites in 
strata 1, 3, and 5 of IPL, and cell bodies of GCL and INL (Fig. 3.3 a, arrows). These NPY-ir cells 
were already described as amacrine cells (Oh et al., 2002). A low intensity Y1 receptor-ir was 
detected in GCL similar to the immunoreactivity found in cultured RGCs (Fig. 3.3 b, arrow). Y2 
receptor-ir was found in stratum 1 of IPL and in cell bodies in proximal INL (Fig. 3.3 c, arrow). 
Y4 receptor-ir was localized in cell bodies of GCL, and proximal and distal INL (Fig. 3.3 d, white 
arrows). The cell bodies in GCL that were immunoreactive for Y4 receptor were both RGC (co-
localized with Brn3a, Fig. 3.3 d, green arrow) and non-Brn3a-positive cells, likely displaced 
amacrine cells (Fig. 3.3 d, yellow arrow). Concerning Y5 receptor, immunoreactivity was 
detected in Müller cells (Fig. 3.3 e, arrow). Co-localization of Y5 receptor-ir with vimentin in 
Müller cells confirmed this result (Fig. 3.4). The lack of clear immunoreactivity for NPY, and for 
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Y2 and Y5 receptors in RGCs in retinal sections of adult rat (Fig. 3.3), while it could be found in 
cultured RGCs from P3-4 rats (Fig. 3.2), may indicate decreased expression in adulthood. 
Figure 3.1. Detection of mRNA expression by RT-PCR for NPY and NPY receptors (Y1, Y2, Y4, and 
Y5) in RGCs purified by immunopanning. NPY and NPY receptors mRNA was detected in RGCs 
isolated from the retinas either pups or young adults Long Evans and Wistar rats. The clear presence 
of Brn3a mRNA and the barely detected mRNAs for GFAP (macroglial cell marker) and Cd11b 
(microglial cell marker) indicate high purity of the isolated RGCs. L, DNA ladder. 
Figure 3.2. NPY and NPY receptor immunoreactivity (ir) in purified RGC cultures. Cell cultures were 
obtained from Wistar pups, purified by immunopanning and cultured for 16 h. NPY (a, red) and NPY 
receptor-ir (b-e, red) were detected in Brn3a (RGC marker, green) positive cells. Nuclei are stained 
with DAPI (blue). Scale bar: 20 μm. 
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Figure 3.3. NPY-ir and NPY receptor-ir in the rat retina. Retinal slices were obtained from young 
adult Wistar rats. RGCs were stained with the RGC marker Brn3a (green) and nuclei with DAPI (blue). 
NPY-ir was detected in strata 1, 3, and 5 of IPL (a, red, arrows). Y1-ir was detected in GCL (b, red, 
arrow). Y2-ir was detected in INL (c, red, arrow). Y4-ir was detected in INL and GCL (d, red, arrows) 
and Y5-ir was detected in Müller cells (e, red, arrow). GCL, ganglion cell layer; IPL, inner plexiform 
layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer. Scale bar: 50 
μm. 
 
Figure 3.4. Immunoreactivity for Y5 receptor in Müller cells in the rat retina. Y5-ir (a, red) is co-
localized (c) with vimentin in Müller cells (b, green) in retinal slices. Müller cells were identified by 
vimentin-ir (green). Nuclei were stained with DAPI (blue). GCL, ganglion cell layer; IPL, inner 
plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer. Scale 
bar: 50 μm. 
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3.2.2 – NPY stimulates functional binding in retinal slices 
 
 We performed [35S]GTPγS binding assay to assess the functional activity of NPY 
receptors in retinal slices from adult Wistar rats (Fig. 3.5). [35S]GTPγS binding assay is able to 
evaluate the activation of G-protein-coupled receptors (GPCRs) by measuring the amount of 
radiolabeled GTP bound to the cell membrane using an autoradiography film. After incubation 
with 10 µM NPY for 60 min, we detected an increase in [35S]GTPγS binding in inner retinal 
layers (134.5 ± 6.4% comparing to basal conditions, non-stimulated retinal slices; Fig. 3.5 A 
and B). Autoradiography films did not allow obtaining higher magnification/resolution imaging 
of retinal slices due to the small size of retinal tissue and low [35S]GTPγS binding signal (Fig. 
3.5 A). However, when comparing the hematoxylin-eosin staining of native retinal slices with 
MR autoradiography film pictures of the same retinal slices, we found that the retinal layers 
presenting increased [35S]GTPγS binding upon NPY stimulation were both GCL and IPL. It is 
also of note the intense binding signal detected in photoreceptor layer both in basal and NPY-
stimulated conditions (Fig. 3.5 Aa and Ab, white arrows) that likely represents the high amount 
of G proteins in photoreceptor outer segments, mainly transducin (Arshavsky et al., 2002). 
Moreover, NPY did not induce a statistically significant increase in binding signal in 
photoreceptor layer. Since 1 µM NPY was not sufficient to increase [35S]GTPγS binding in 
retinal sections, we speculated that low levels of NPY receptors were functionally active in 
frozen retinal sections, thus requiring increased concentrations of NPY. A cocktail of NPY 
receptor antagonists (10 µM BIBO 3304 for Y1; 10 µM BIIE 0246 for Y2; 100 µM L-152,804 for 
Y5) was used to evaluate the selectivity of NPY-stimulated [35S]GTPγS binding. The blockade of 
Y1, Y2, and Y5 receptors prevented the increased binding induced by NPY confirming the 
selectivity of binding signal. To assess the non-specific binding (NSB), a competitive control 
with non-radioactive GTPγS was used, which exhibit no clear binding signal in MR 
autoradiography film (Fig. 3.5 Ad). 
  
Neuropeptide Y in the Retina 
 
77 
 
Figure 3.5. NPY increases [35S]GTPγS binding in retinal sections. (A) Examples of retinal sections 
from MR autoradiography films after [35S]GTPγS binding assay. (B) Quantification of [35S]GTPγS 
binding in inner retinal layers. Incubation with 10µM NPY increased the [35S]GTPγS binding in inner 
retinal layers (Ab, black arrow) compared to basal binding (Aa). An intense signal was found in 
photoreceptor layer (white arrows) both in basal and NPY-stimulated binding conditions that may 
represent the high amount of G proteins in photoreceptor outer segments, mainly transducin. The 
blockade of Y1, Y2, and Y5 receptors prevented the increased [35S]GTPγS binding induced by NPY 
(Ac). NSB refers to non-specific binding, a competitive control with non-radioactive GTPγS (Ad). 
Antagonists used: Y1, BIBO 3304 (10 µM); Y2, BIIE 0246 (10 µM); Y5, L-152,804 (100 µM). Bar: 2 mm. 
Data are presented as mean ± SEM of n = 8-10 independent experiments, except 1µM NPY, which 
was not used for statistical comparisons (n = 2). ***p<0.001, compared to basal; ###p<0.001, 
compared to 10 µM NPY. One-way ANOVA followed by BonferroŶi’s test. 
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3.2.3 – NPY attenuates glutamate-induced [Ca2+]i increase in purified retinal ganglion cells 
 
 We aimed to evaluate the modulatory effect of NPY directly on RGCs. For this purpose, 
we cultured purified RGCs and performed intracellular free calcium concentration - [Ca2+]i, 
measurements using Fura-2 calcium indicator. Following a similar protocol described 
previously (Hartwick et al., 2004), we stimulated RGCs with different glutamate 
concentrations (1 to 1000 µM) for 30 sec, including also 10 µM glycine (Methods section). 
After testing these glutamate concentrations, in the following experiments we used 30 µM 
glutamate since this concentration was able to induce a non-saturating increase in [Ca2+]i that 
was easily reversible. The ratios between emissions of Fura-2 when excited by light at 340 nm 
and 380 nm wavelengths were quantified in cell bodies of RGCs, as indicative of [Ca2+]i. After 
the first glutamate stimulus, we applied different drugs for 10 min: NPY (1 µM), the Y1/Y5 
agonist (Leu31, Pro34)-NPY (1 µM), the Y2 agonist NPY (13-36) (300 nM), and the Y5 agonist 
(Gly1, …Aiď32)-PP (1 µM), or a drug-free solution (control), followed by a second glutamate 
stimulus (Fig. 3.6 A). The increase above basal Fura-2 ratio was quantified for each stimulus as 
a Delta value. When evaluating the average [Ca2+]i responses of the cell population analysed, 
a small decrease in Delta 2 / Delta 1 ratios was found for NPY (0.83 ± 0.04) and (Leu31, Pro34)-
NPY (0.81 ± 0.05), compared to control (0.93 ± 0.02) (Fig. 3.6 C). In fact, a small significant 
change may be hard to detect within the overall population, as can be observed in scatter 
plots showing individual RGCs from an independent experiment (Fig. 3.6 D). Hence, we 
quantified the percentage of RGCs where the Delta 2 / Delta 1 ratio value was lower than 0.9 
(Fig. 3.6 E). The application of NPY or (Leu31, Pro34)-NPY for 10 min significantly increased the 
percentage of cells with Delta 2 / Delta 1 ratio below 0.9 (77.7 ± 10.3% or 68.5 ± 8.3%, 
respectively), compared to control (32.7 ± 8.4%). Since the Y5 receptor agonist alone was not 
able to affect the RGC response to glutamate, it is likely that the effect of NPY or (Leu31, Pro34)-
NPY might occur via Y1 receptor activation. 
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Figure 3.6. NPY attenuates glutamate-induced [Ca2+]i increase in purified RGCs. (A) Schematic 
experimental protocol for Ca2+ imaging in RGCs. After the first glutamate stimulus (30 µM for 30 
sec) and a period of washout for at least 210 sec, 1 µM NPY, 1 µM (Leu31, Pro34)-NPY, 300 nM NPY 
(13-36), 1µM (Gly1, …Aiď32)-PP, or a drug-free solution (control), were applied to RGCs during 10 
min followed by a second glutamate stimulus and washout. (B) Examples of [Ca2+]i traces of RGC 
responses to consecutive glutamate stimuli (30 µM) for 30 sec each stimulus. After the first 
glutamate stimulus, 1 µM NPY or a drug-free solution (control) were applied to RGCs during 10 min 
followed by a second glutamate stimulus. (C) The increase above basal Fura-2 ratio 340 nm / 380 
nm was quantified for each stimulus as a Delta value. The Delta 2 (2nd stimulus) / Delta 1 (1st 
stimulus) ratios are presented for different drug applications for 10 min: 1 µM NPY, 1 µM (Leu31, 
Pro34)-NPY, 300 nM NPY (13-36), 1µM (Gly1, …Aiď32)-PP, or a drug-free solution (control). A small 
decrease in Delta 2 / Delta 1 ratios may be found in RGCs exposed to NPY and (Leu31, Pro34)-NPY. 
(D) Scatter plots for two populations of RGCs from the same independent experiment show the 
dispersion of Delta 2 / Delta 1 ratio values among cells. RGCs were treated with a drug-free solution 
(control) or NPY. Note that in NPY-treated population a small downward shift may be observed. 
Dashed line indicate 0.9 ratio value. (E) Percentage of cells presenting Delta 2 / Delta 1 ratio below 
0.9 was quantified. The application of NPY or (Leu31, Pro34)-NPY for 10 min increased the percentage 
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of cells with Delta 2 / Delta 1 ratio below 0.9. Data are presented as mean ± SEM of n = 5-10 
independent experiments. *p<0.05, compared to control. Kruskal-Wallis folloǁed ďǇ DuŶŶ’s test. 
 
 
3.2.4 – RGC spiking activity is modulated by Y1 receptor activation 
 
 Since NPY is able to modulate neuronal activity in various brain regions (Silva et al., 
2002; Benarroch, 2009), we hypothesized whether direct application of NPY to ex vivo retinas 
could modulate RGC spiking activity. For this purpose, we used a MEA system allowing 
recording spiking activity from various RGCs within a square of 0.6 mm2 comprising 60 
electrodes arranged in an 8×8 layout. After spike sorting based on template matching, the 
spiking rate for individual RGCs was quantified. In the first set of experiments, we recorded 
RGC spontaneous activity before (Baseline) and after the application of NPY (1 µM), the Y1/Y5 
agonist (Leu31, Pro34)-NPY (1 µM), the Y2 agonist NPY (13-36), (1 µM), or a drug-free solution 
(control) for 10 min under continuous perfusion (Fig. 3.7 A). In addition, a period of washout 
up to 60 min was included. We found a small decrease in RGC spiking rate over time reaching 
79.5 ± 7.2% of Baseline in control at 60 min of washout (Fig. 3.7 B). However, exposure to NPY 
or NPY receptor agonists caused no effect since RGCs presented a decrease in spiking rate 
similar to control. 
  
Neuropeptide Y in the Retina 
 
81 
 
 
Figure 3.7. NPY or NPY receptor agonists do not changed the spontaneous activity of RGCs. (A) Ex 
vivo retinal preparations were exposed to 1 µM NPY, 1 µM (Leu31, Pro34)-NPY, 1µM NPY (13-36), or 
a drug-free solution (control) for 10 min followed by 60 min of washout. Arrows indicate when MEA 
recordings were performed. Open arrow indicates Baseline recording. (B) Quantification of RGC 
spontaneous spiking rate. A decrease in RGC spiking rate was observed over time, though no effects 
were found for drug treatments. 
 
In order to evaluate the effect of NPY on RGC light responses, ex vivo retinas were 
exposed to light stimuli in the photopic range (5.0 cd/m2), while RGC spiking activity was 
recorded in the MEA system. The light stimulation protocol consisted of 10 consecutive 
stimulation blocks composed of 5 sec light followed by 10 sec dark. RGC light responses were 
classified as ON- or OFF-type. An ON-type RGC light response was considered if increased 
spiking activity was detected at light onset and an OFF-type RGC light response was considered 
when increased spiking activity was detected at dark onset in each stimulation block. The most 
common RGC light response detected with our stimulation protocol was a transient response, 
either ON- or OFF-type, characterized by an initial burst response to light or dark onset, 
respectively, which was followed by a rapid decrease in spiking activity. We also detected a 
few RGC light responses classified as sustained, which were characterized by a sustained 
increase in spiking activity during the full light or dark period of a stimulation block and were 
included in ON- or OFF-type groups, respectively. The peri-stimulus time histograms (PSTHs) 
were generated from RGC responses to 9 consecutive stimulation blocks and used to calculate 
the initial burst responses to light or dark onset, as well as the mean spiking rates during the 
first 1 or 5 sec after light or dark onset, ON- or OFF-type responses, respectively. The latencies 
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of RGC light responses were also calculated. The first RGC light response to a series of 10 
stimulation blocks was always excluded since it was harder to apply the spike sorting 
procedure due to increased noise in the raw recordings. Thus, in order to evaluate the 
potential modulatory effect of NPY on RGC light responses, the recordings were performed 
before (Baseline) and after the application of NPY (1 µM), the Y1/Y5 agonist (Leu31, Pro34)-NPY 
(1 µM), the Y2 agonist NPY (13-36), (1 µM), or a drug-free solution (control) for 10 min under 
continuous perfusion. Regarding ON-type light response, no effect was found on the initial 
burst of spiking activity to light onset for the drugs used (Fig. 3.8 A). The same was observed 
for 1 and 5 sec rate, and also for latency of ON-type RGCs (Fig. 3.8 B, C, D, respectively). 
However, the application of 1 µM (Leu31, Pro34)-NPY for 10 min was able to induce a small, but 
statistically significant, increase to 112.4 ± 2.8% of baseline on the initial burst of spiking 
activity triggered by dark onset in OFF-type RGCs (Fig. 3.9 A), when compared to control (100.3 
± 1.1% of baseline). Although a small increase may be observed for 1 (Fig. 3.9 B) and 5 sec rate 
(Fig. 3.9 C) after the application of (Leu31, Pro34)-NPY, no statistically significant differences 
were found. Also, no statistically significant differences were found after the application of 1 
µM NPY or 1 µM NPY (13-36). This result suggests that Y1 or Y5 activation may be sufficient to 
modulate the OFF-type RGC light response directly by changing the receptive field properties 
or acting upstream of RGCs in the vertical pathway of visual information, namely at the level 
of bipolar or photoreceptor cells. Concerning latency quantification of OFF-type RGC light 
responses, no effect was found after the different drug treatments used (Fig. 3.9 D). 
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Figure 3.8. NPY or NPY receptor agonists do not change the magnitude and latency of ON-type 
RGC light responses. (A) Quantification of the Initial burst to light onset of ON-type RGCs after 
application of the same drug treatments as in Fig 3.7 A. No effect was found for the different drug 
treatments compared to control. Similarly, no effect of drug treatments was found for 1 (B) and 5 
sec rate (C), and also for the latency of ON-type RGCs (D). All data were normalized to the values 
obtained before drug application (Baseline). Data are presented as mean ± SEM of n = 3-4 
independent experiments. 
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Figure 3.9. (Leu31, Pro34)-NPY increases the response of OFF-type RGCs to dark onset. (A) 
Quantification of the Initial burst to dark onset of OFF-type RGCs after application of the same drug 
treatments as in Fig. 3.7 A. The application of 1 µM (Leu31, Pro34)-NPY for 10 min was able to increase 
the magnitude of OFF-type response compared to control. Although a small increase may be 
observed for 1 (B) and 5 sec rate (C) after the application of (Leu31, Pro34)-NPY, no statistically 
significant differences were found. Concerning latency quantification for OFF-type RGCs (D), no 
effect was detected after the application of different drugs. All data were normalized to the values 
obtained before drug application (Baseline). Data are presented as mean ± SEM of n = 3-4 
independent experiments. *p<0.05, compared to control. Kruskal-Wallis folloǁed ďǇ DuŶŶ’s test. 
 
 In addition to light stimulation experiments, we also evaluated the potential 
modulatory effect of NPY application on RGC spiking activity upon glutamate receptor 
activation. Glutamate is easily cleared within the retina by glutamate uptake (Higgs and 
Lukasiewicz, 1999), and therefore, we applied NMDA directly to ex vivo retinas in order to 
induce synaptic excitation of RGCs (Fig. 3.10 A, B), since NMDA receptors are abundantly 
expressed in RGCs (Shen et al., 2006). The application of NMDA (30 µM) for 5 min induced an 
acute increase in RGC spiking activity which was reversible within 10 min of washout (Fig. 3.10 
A, B). After washout of the 1st NMDA stimulus different drugs were applied for 10 min under 
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continuous perfusion: NPY (1 µM), the Y1/Y5 agonist (Leu31, Pro34)-NPY (1 µM), the Y2 agonist 
NPY (13-36) (1µM), the Y5 agonist (Gly1, …Aiď32)-PP (1µM), or a drug-free solution (control). 
After 10 min of drug treatment a 2nd NMDA stimulus was co-applied, followed by 10 min of 
washout. The increase above basal spiking rate (Baseline) or above washout was quantified 
for each NMDA stimulus as a Delta value (Fig. 3.10 B). Subsequently, the Delta 2 (2nd stimulus) 
/ Delta 1 (1st stimulus) ratios were calculated for each individual RGC. We found that 
application of (Leu31, Pro34)-NPY was able to decrease the Delta 2 / Delta 1 ratio to 0.67 ± 0.07, 
when compared to control, 0.96 ± 0.04 (Fig. 3.11 A), indicating that activation of Y1 or Y5 
receptor was sufficient to attenuate the NMDA-stimulated RGC spiking activity. For the other 
drug treatments, no statistically significant alterations were detected compared to control. 
The effect of (Leu31, Pro34)-NPY was confirmed to be mediated by Y1 receptor activation since 
the co-application of Y1 receptor antagonist BIBP 3226 (1 µM) and (Leu31, Pro34)-NPY was able 
to prevent its effect (Fig. 3.11 A). Moreover, the application of the Y5 receptor agonist alone 
did not affect the RGC response to NMDA, suggesting that the effect found for (Leu31, Pro34)-
NPY is not mediated by Y5 receptor activation. 
In order to focus on the RGCs that presented more pronounced differences between 
responses to 1st and 2nd NMDA stimulus, we calculated the percentage of RGCs presenting 
Delta 2 / Delta 1 ratio values below 0.9 for each independent experiment (Fig. 3.11 B), thus, 
overcoming the masking effect associated with overall population mean calculation. As 
expected, the application of (Leu31, Pro34)-NPY increased the percentage of cells (79.0 ± 6.9% 
of the cells analysed), with Delta 2 / Delta 1 ratio below 0.9, when compared to control (40.8 
± 5.0% of the cells analysed) (Fig. 3.11 B). Also, the Y1 receptor antagonist BIBP 3226 was able 
to prevent the effect of (Leu31, Pro34)-NPY, confirming the involvement of Y1 receptor 
activation. No statistically significant differences were detected for the other drug treatments. 
We hypothesize that a possible opposite effect of Y2 activation might be responsible 
for counteracting the effect of Y1 activation by NPY. In this regard, the application of Y2 agonist 
NPY (13-36) resulted in a Delta 2 / Delta 1 ratio of 1.2 ± 0.1 (Fig. 3.11 A), and the percentage 
of cells with Delta 2 / Delta 1 ratio below 0.9 was 24.8 ± 7.2% (Fig. 3.11 B), both values 
apparently in opposite direction of Y1 receptor activation, though no statistically significant 
differences were detected.  
CHAPTER 3 
 
86 
 
Figure 3.10. Y1 receptor activation decreases NMDA-stimulated RGC spiking activity. (A) NMDA 
(30 µM) was applied for 5 min followed by a washout period of 10 min. Then, 1 µM NPY, 1 µM 
(Leu31, Pro34)-NPY, 1 µM NPY (13-36), 1 µM (Gly1, …Aiď32)-PP, or a drug-free solution (control) were 
applied under continuous perfusion. A 2nd NMDA stimulus for 5 min was co-applied with drug 
solutions after 10 min of drug application. Arrows indicate when MEA recordings were performed. 
Open arrow indicate Baseline recording. (B) The increase above basal spiking rate (Baseline) or 
above washout was quantified for each NMDA stimulus as a Delta value. (C) Representative 
recordings of RGC spiking activity recorded in ex vivo retina using a MEA. Note the increase in 
spiking rate upon 30 µM NMDA. After washout of 1st NMDA stimulus, 1 µM (Leu31, Pro34)-NPY was 
applied for 10 min followed by a 2nd NMDA stimulus. Note that the NMDA-induced increase in RGC 
spiking activity was reduced upon application of (Leu31, Pro34)-NPY. 
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Figure 3.11. Activation of Y1 receptors decreases NMDA-stimulated RGC spiking activity. (A) The 
Delta 2 (2nd stimulus) / Delta 1 (1st stimulus) ratios for different drug applications, for 10 min, 
between NMDA stimuli: 1 µM NPY, 1 µM (Leu31, Pro34)-NPY, 1 µM NPY (13-36), 1 µM (Gly1, …Aiď32)-
PP, or a drug-free solution (control). The application of (Leu31, Pro34)-NPY was able to reduce the 
NMDA-stimulated RGC spiking activity. This effect was blocked by the Y1 receptor antagonist BIBP 
3226 (1 µM). (B) Percentage of RGCs presenting Delta 2 / Delta 1 ratio below 0.9. The application 
of (Leu31, Pro34)-NPY increased the percentage of cells with Delta 2 / Delta 1 ratio below 0.9. BIBP 
3226 was able to block the effect of (Leu31, Pro34)-NPY confirming the involvement of Y1 receptor 
activation. Data are presented as mean ± SEM of n = 3-10 independent experiments. **p<0.01, 
compared to control; #p<0.05, compared to (Leu31, Pro34)-NPY. Kruskal-Wallis folloǁed ďǇ DuŶŶ’s 
test. 
 
3.2.5 – NPY prevents NMDA-induced cell death in retinal explants via Y1 and Y5 receptor 
activation 
 
NPY exerts neuroprotective actions in various brain regions, and also in the retina 
(Alvaro et al., 2008b; Santos-Carvalho et al., 2013b), suggesting that NPY receptors might be 
possible therapeutic targets for retinal diseases such as glaucoma. Therefore, in addition to 
the modulatory effect of NPY on RGC activity detected in ex vivo retinas, we also evaluated 
whether NPY could be able to prevent retinal cell death induced by an excitotoxic insult. The 
excitotoxic insult was induced in retinal explants (cultured for 4 DIV) exposed to 300 µM 
NMDA for 48 h. Different drug treatments were applied to assess the potential protective 
effect of NPY receptor activation. Thus, NPY (1 µM), the Y1/Y5 agonist (Leu31, Pro34)-NPY (1 
µM), the Y2 agonist NPY (13-36), (300 nM), or the Y5 agonist (Gly1, …Aiď32)-PP (1 µM) were 
applied at DIV1 and DIV2, respectively 24 h and 60 min before NMDA treatment (Fig. 3.12).  
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Figure 3.12. Schematic representation of the experimental protocol used for NMDA-induced cell 
death in retinal explants. The scheme shows the drug application protocol in retinal explants, 
cultured for 4 days, in order to evaluate the potential neuroprotective effect of NPY and NPY 
receptor agonists. Retinal explants were exposed to 300 µM NMDA for 48 h to induce an excitotoxic 
insult. Pre-treatment with NPY or NPY receptor agonists was performed 24 h and 60 min before 
NMDA. NPY receptor antagonists were applied 30 min before NPY or NPY receptor agonists. 
 
Apoptotic retinal cell death was assessed by TUNEL assay (Fig. 3.13) and necrotic or 
late apoptotic cell death was assessed by PI incorporation assays (Fig. 3.14). 
In TUNEL assay experiments, we quantified TUNEL-positive cells localized in GCL, using 
confocal microscopy, since this layer is highly affected in diseases like glaucoma (Fig. 3.13 A). 
TUNEL-positive cell counts were then normalized to the value obtained in non-treated retinal 
explant (control), in each independent experiment (Fig. 3.13 B). In PI assay experiments, since 
the acquisition of images was performed with live retinal explants using fluorescence 
microscopy, we quantified PI-positive cells across all retinal layers. PI-positive cells were 
quantified at DIV2 (before NMDA application) and at DIV4. The ratio between PI-positive cells 
at DIV4 and DIV2 was calculated to evaluate the effect of NMDA on necrotic or late apoptotic 
cell death (Fig. 3.14). 
Exposure of retinal explants to NMDA for 48 h increased the number of TUNEL-positive 
cells in the GCL up to 16.3 ± 1.3 times higher than in control (Fig. 3.13 B). There was also an 
increase in the DIV4 / DIV2 ratio for PI-positive cells compared to control (3.4 ± 0.2 in NMDA-
treated explants versus 1.3 ± 0.1 in control) (Fig. 3.14). Pre-treatment with NPY was able to 
prevent the increase in the number of TUNEL-positive cells induced by NMDA to 4.8 ± 0.5. NPY 
pre-treatment was also able to prevent the increase in DIV4 / DIV2 ratio for PI-positive cells 
(1.4 ± 0.2) (Fig. 3.14). The Y1 antagonist BIBP 3226 (1 µM), or the Y5 antagonist L-152,804 (1 
µM), when applied 30 min before NPY, were able to block its protective effect both on TUNEL 
and PI assays, indicating the involvement of Y1 and Y5 receptor activation on the 
neuroprotective effects of NPY. The protective effect of Y1 receptor activation was confirmed 
by the application of (Leu31, Pro34)-NPY which was able to reduce the NMDA-induced increase 
in TUNEL- and PI-positive cells. Again, the Y1 antagonist BIBP 3226 blocked this effect. 
Concerning the Y5 receptor activation, the use of (Gly1, …Aiď32)-PP, might have reduced the 
number of TUNEL-positive cells, comparing to NMDA-treated explants, though no statistically 
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significant differences were detected. However, it was able to reduce the number of PI-
positive cells compared to NMDA condition. This later effect was blocked by L-152,804, thus 
confirming the protective effect of Y5 receptor activation. The Y2 receptor was not involved in 
the protective action of NPY since the Y2 antagonist BIIE 0246 (1 µM) did not block the 
neuroprotective effect of NPY. Also, NPY (13-36) did not prevent the increase in TUNEL- and 
PI-positive cells induced by NMDA in retinal explants. 
 
Figure 3.13. NPY prevents NMDA-induced cell death in the GCL in retinal explants via Y1 and Y5 
receptor activation. (A) Representative images of TUNEL-positive cells (green) in the GCL of control 
(a) or NMDA-treated (b-f) retinal explants. Nuclei were stained with DAPI (blue). Retinal explants 
were pre-treated with different drugs 24 h before exposure to NMDA. Scale bar: 100 µm. (B) 
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Quantification of TUNEL-positive cells. NMDA exposure induced a significant increase in the number 
of TUNEL-positive cells in the GCL compared to control. Pre-treatment with 1 µM NPY or 1 µM 
(Leu31, Pro34)-NPY (Y1/Y5 agonist), 24 h before NMDA, was able to prevent the increase in the 
number of TUNEL-positive cells induced by NMDA. Pre-treatment with Y1 or Y5 receptor antagonist 
(1 µM BIBP 3226 or 1 µM L-152,804, respectively), when applied 30 min before NPY, blocked its 
protective effect. The effect of (Leu31, Pro34)-NPY was blocked by BIBP 3226. Data are presented as 
mean ± SEM of n = 5-11 independent experiments. ***p<0.001, compared to control; ##p<0.01, 
compared to NMDA; §p<0.05, §§p<0.01, compared to NMDA + NPY, or NMDA + (Leu31, Pro34)-NPY. 
Kruskal-Wallis folloǁed ďǇ DuŶŶ’s test. 
Figure 3.14. NPY prevents NMDA-induced cell death in retinal explants via Y1 and Y5 receptor 
activation. NMDA exposure induced a significant increase in the number of PI-positive cells in 
retinal explants. Data are presented as the ratio between PI-positive cells at DIV4 and DIV2. NPY or 
(Leu31, Pro34)-NPY (Y1/Y5 agonist) was able to prevent the increase in the number of PI-positive cells 
induced by NMDA. BIBP 3226 or L-152,804 (Y1 or Y5 antagonist, respectively) blocked the protective 
effect of NPY, and BIBP 3226 blocked the protective effect of (Leu31, Pro34)-NPY. The application of 
1µM (Gly1, …Aiď32)-PP was able to prevent the increase in PI-positive cells induced by NMDA, and 
this effect was blocked by L-152,804. This result suggests that NPY is able to protect retinal cells 
from an excitotoxic insult through the activation of Y1 and Y5 receptors. Data are presented as mean 
± SEM of n = 5-11 independent experiments. ***p<0.001, compared to control; ###p<0.001, 
compared to NMDA; §§p<0.01, §§§p<0.001, compared to NMDA + NPY, or NMDA + (Leu31, Pro34)-
NPY, or NMDA + (Gly1, …Aiď32)-PP. Kruskal-Wallis folloǁed ďǇ DuŶŶ’s test. 
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3.2.6 – NPY does not prevent the reduction in Brn3a-positive RGCs induced by NMDA in 
retinal explants 
 
Brn3a labelling of RGCs has been used as a valid marker to study the survival of RGCs 
in injured retinas (Nadal-Nicolas et al., 2009; Nadal-Nicolas et al., 2012). Retinal explants were 
pre-treated with 1 µM NPY, 24 h and 60 min before exposure to 300 µM NMDA for 48 h (Fig. 
3.15 A).  NMDA exposure induced a significant decrease in the number of Brn3a-positive RGCs 
to 274 ± 51 cells/mm2, compared to control (977 ± 140 cells/mm2; Fig. 3.15 B). However, pre-
treatment with 1µM NPY was not able to prevent this decrease. This result indicates that the 
neuroprotective effect exerted by NPY pre-treatment found in TUNEL and PI assays might 
restrict to amacrine cells and does not extend to RGCs. 
 
Figure 3.15. NPY does not prevent NMDA-induced reduction in Brn3a-positive RGCs in retinal 
explants. (A) Representative images of Brn3a-positive RGCs (red) in the GCL of control (a) or NMDA-
treated (b, c) retinal explants. Retinal explants were pre-treated with 1 µM NPY, 24 h and 60 min 
before exposure to 300 µM NMDA for 48 h. Scale bar: 100 µm. (B) NMDA exposure induced a 
significant decrease in the number of Brn3a-positive RGCs compared to control. Pre-treatment with 
1 µM NPY was not able to prevent this decrease. Data are presented as mean ± SEM of n = 9-12 
independent experiments. ***p<0.001, compared to control. One-way ANOVA followed by 
BoŶferroŶi’s test.  
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3.2.7 – Intravitreal administration of NPY does not prevent cell death induced by I-R injury 
 
In addition to cultured retinal explants, we also explored the potential neuroprotective 
action of NPY in an animal model of retinal damage induced I-R injury (Fig. 3.16 A). Retinal 
ischemia was induced for 60 min followed by 24 h of reperfusion. Ischemia was induced in one 
eye, and the contralateral eye was taken as an internal control. Saline or 10 µg (2.34 nmol) 
NPY were intravitreally injected 2 h before the onset of I-R injury. Retinal cell death was 
assessed by TUNEL-assay (Fig. 3.16 B). I-R injury induced an increase in the number of TUNEL-
positive cells per mm of retinal section length to 31.8 ± 6.6 compared to contralateral eye (0.6 
± 0.3 TUNEL-positive cells across all the retinal nuclear layers) (Fig. 3.16 C). This increase was 
not prevented by pre-treatment with NPY. RGC survival was evaluated using the RGC marker 
Brn3a (Nadal-Nicolas et al., 2012). We found that I-R injury decreased the number of Brn3a-
positive RGCs per mm of retinal section length to 12.0 ± 2.5 RGCs compared to the 
contralateral eye (26.0 ± 4.5), and again, this effect was not prevented by NPY administration 
(Fig. 3.16 D). 
We also performed ERGs in order to assess the functional effect of I-R injury on retinal 
light responses. Scotopic and photopic ERGs were recorded before the onset of I-R injury 
(Baseline) and after 24 h of reperfusion (Fig. 3.17). The obtained ERG values for amplitudes 
and latencies were normalized to baseline ERG. We found that the a-wave amplitude was not 
affected by I-R injury (Fig. 3.18). However, I-R reperfusion injury induced decreased b-wave 
amplitudes, to 37.7 ± 11.0% of baseline ERG for scotopic ERG (Fig. 3.18 C) and to 10.1± 5.6% 
of baseline ERG for photopic ERG (Fig. 3.18 E). The amplitudes of scotopic b-wave were 
reduced in all three animals tested, although no statistically significant differences were 
detected (Fig. 3.18 C). Also, the latencies for scotopic a-wave and b-wave, and photopic b-
wave were not affected by I-R injury (Fig. 3.18 B, D, F, respectively). Similarly to what was 
found regarding TUNEL and Brn3a results (Fig. 3.16), NPY administration before I-R injury did 
not prevent the reduction in ERG b-wave amplitudes, both scotopic and photopic (Fig. 3.18 C, 
E, respectively). Together, these results indicate that, contrarily to the protective action 
against an excitotoxic injury in retinal explants, NPY pre-treatment was not able to prevent 
retinal I-R injury within 24 h of reperfusion. Therefore, further studies are needed in order to 
evaluate whether NPY neuroprotective action translates to in vivo models of retinal diseases. 
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Figure 3.16. Intravitreal administration of NPY is not able to prevent cell death induced by I-R 
injury at 24 h of reperfusion. (A) Schematic representation of the protocol of retinal I-R injury and 
intravitreal administration. Retinal ischemia was induced for 60 min followed by 24 h of 
reperfusion. Saline, or 10 μg NPY, were intravitreally injected 2 h before the onset of I-R injury. 
Arrows indicate the ERG recordings, performed before (Baseline, open arrow) and 24 h after I-R 
injury (grey arrow). Ischemia was induced in one eye, and the contralateral eye was taken as an 
internal control. (B) Representative images of retinal sections showing TUNEL-positive cells (green) 
and Brn3a-positive RGCs (red). Nuclei were stained with DAPI (blue). Saline (a, c), or 10 μg NPY (b, 
d) were intravitreally injected 2 h before the onset of I-R injury. GCL, ganglion cell layer; IPL, inner 
plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer. Scale 
bar: 50 µm. (C) TUNEL-positive cells are expressed per mm of retinal section length. I-R injury 
induced an increase in the number of TUNEL-positive cells. NPY administration was not able to 
reduce the number of TUNEL-positive cells. (D) Brn3a-positive RGCs were expressed per mm of 
retinal section length. NPY administration was not able to prevent the reduction in Brn3a-positive 
RGC number induced by I-R injury. Data are presented as mean ± SEM of n = 6 independent 
experiments. *p<0.05, **p<0.01, compared to Contralateral eye. Kruskal-Wallis folloǁed ďǇ DuŶŶ’s 
test. 
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Figure 3.17. Intravitreal administration of NPY is not able to prevent ERG changes induced by I-R 
injury at 24 h of reperfusion. Ischemia was induced in one eye, and the contralateral eye was taken 
as an internal control. Examples of scotopic ERG traces for saline (a, c) and NPY-treated eyes (b, d). 
ERG recordings were performed before (Baseline) and 24 h after I-R injury. Note that in the injured 
eye the b-wave was abruptly reduced (c). NPY administration did not prevent the reduction in b-
wave (d). 
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Figure 3.18. Intravitreal administration of NPY was not able to prevent ERG changes induced by I-R 
injury. Ischemia was induced in one eye, and the contralateral eye was taken as an internal control. 
Quantification of a-wave amplitude (A) and latency (B), scotopic b-wave amplitude (C) and latency (D), 
and photopic b-wave amplitude (E) and latency (F). In the injured eye (I-R eye), the a-wave amplitude 
was not affected (A), but the b-wave amplitude was decreased (C, E). For the a-wave and b-wave 
latencies, no changes were detected (B, D, E). NPY administration did not prevent the reduction in b-
wave amplitudes (C, D). Data are presented as mean ± SEM of n = 3 independent experiments. *p<0.05, 
compared to Contralateral eye. Kruskal-Wallis folloǁed ďǇ DuŶŶ’s test. 
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3.3 – Discussion 
 
In this study, we evaluated the presence and localization of NPY and NPY receptors in 
the rat retina, particularly at RGC level. The presence of mRNA for both NPY and NPY receptors 
(Y1, Y2, Y4, and Y5) in the rat retina have been demonstrated in previous studies (D'Angelo and 
Brecha, 2004; Alvaro et al., 2007). We now present evidence supporting the presence of NPY 
and NPY receptors specifically in acutely isolated RGCs from both Wistar and Long Evans rats 
obtained from P3-4 pups or adult animals (Fig. 3.1). NPY-ir in the retina has been extensively 
evaluated in different species (Santos-Carvalho et al., 2014). In human retina, NPY-ir was 
shown to be confined to a subset of amacrine cells and RGCs, which processes extend mainly 
in the IPL and occasionally in the OPL (Tornqvist and Ehinger, 1988; Straznicky and Hiscock, 
1989). In rat retina, NPY-ir was reported to localize in cell bodies of amacrine cells in INL and 
displaced amacrine cells in GCL and to co-localize mainly with gabaergic neurons. The 
corresponding cell processes extend and ramify mainly in strata 1, 3, and 5 of IPL, and very 
occasionally in OPL (Oh et al., 2002). We confirmed these observations in the rat retina using 
retinal slices of adult rats and showing NPY-ir in cell bodies of GCL and INL and in ramified 
dendrites in strata 1, 3, and 5 of IPL (Fig. 3.3). In addition, we found NPY-ir in a purified culture 
of RGCs obtained from P3-4 pups. In a previous study, we have also suggested the presence 
of NPY-ir in different retinal cell types in a primary culture of retinal cells (Alvaro et al., 2007). 
Regarding the localization of NPY receptors in the retina, few studies addressed this 
issue. In human retina, transcripts for Y1, Y2, and Y5 receptors were detected in RPE (Ammar 
et al., 1998). Y1 receptor-ir was detected in glial cells of diseased human retina and in 
horizontal and amacrine cells of rat retina (Canto Soler et al., 2002; D'Angelo et al., 2002), and 
we have previously detected immunoreactivity for Y1 and Y2 receptors in neurons and glial 
cells in cultured retinal cells (Santos-Carvalho et al., 2013a). Moreover, we and others have 
reported functional evidence suggesting the presence of Y1, Y2, Y4, and Y5 receptors in retinal 
cells (Bruun et al., 1994; D'Angelo and Brecha, 2004; Milenkovic et al., 2004; Alvaro et al., 
2008a; Alvaro et al., 2009; Santos-Carvalho et al., 2013b). Regarding purified RGC cultures, we 
detected immunoreactivtiy for NPY and Y1, Y2, Y4, and Y5 receptors in Brn3a-positive RGCs. In 
retinal sections, Y1-ir was found in GCL, in agreement with the labelling found in purified RGC 
cultures. Using an antigen retrieval step, we indeed detected Y2, Y4, Y5 receptor-ir in retinal 
sections. Y2 receptor-ir was found in stratum 1 of IPL and in cell bodies in proximal INL. Y4 
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receptor-ir was localized in cell bodies of GCL, and proximal and distal INL. The cell bodies in 
GCL that were immunoreactive for Y4 receptor were both RGC (co-localized with Brn3a) and 
non-Brn3a-positive cells, likely displaced amacrine cells. Concerning Y5 receptor, 
immunoreactivity was detected in Müller cells confirmed by co-localization with vimentin (Fig. 
3.4). The lack of clear immunoreactivity for NPY, and for Y2 and Y5 receptors in RGCs in retinal 
sections of adult rat, while it could be found in cultured RGCs from P3-4 rats, may be explained 
by decreased expression in adulthood or related with the cell culture conditions, which might 
favour the expression of NPY or NPY receptors. In addition to immunofluorescence data, we 
present further evidence showing the presence of functional active NPY receptors in the inner 
retina using [35S]GTPγS binding assay (Fig. 3.5). Binding signal detected in the photoreceptor 
layer might represent the high amount of G proteins in photoreceptor outer segments, mainly 
transducin (Arshavsky et al., 2002). 
NPY has been associated with inhibitory actions after electrical or chemical stimulation 
of excitatory synaptic transmission (El Bahh et al., 2002; Tu et al., 2006; Kovac et al., 2011). In 
fact, in different neuronal cell types NPY was reported to decrease depolarization-evoked 
increase in [Ca2+]i by inhibiting voltage-dependent Ca2+ channels. This effect was reported in a 
variety of neuronal cell types such as dorsal root ganglion neurons (Bleakman et al., 1991), 
hippocampal neurons (Bleakman et al., 1992), submandibular ganglion neurons (Endoh et al., 
2012), and hypothalamic arcuate nucleus neurons (Sun and Miller, 1999). In rat thalamic 
neurons, NPY was shown to activate GIRK channels via Y1 and inhibit N and P/Q-type Ca2+ 
channels via Y2 receptor activation (Sun et al., 2001), whereas in arcuate nucleus neurons, NPY 
analogues that activated all of the known NPY receptors (Y1, Y2, Y4, and Y5) were able to both 
inhibit Ca2+ currents and activate inwardly rectifying K+ currents (Sun and Miller, 1999). 
Moreover, the activation of Y1 receptor has been associated with inhibition of 
neurotransmitter release (Bitran et al., 1999; Hastings et al., 2004; Wang, 2005), though the 
opposite can be found depending on the neurotransmitter or cell type (Hastings et al., 2001). 
In the retina, Y2 receptor activation attenuated depolarization-evoked Ca2+ influx in rod bipolar 
cell terminals (D'Angelo and Brecha, 2004). In addition, previous work in our laboratory has 
shown that NPY application to retinal cell cultures was able to reduce depolarization-evoked 
[Ca2+]i increase via activation of Y1 and Y5 receptors (Alvaro et al., 2009). Thus, we now aimed 
to evaluate the effect of direct application of NPY or NPY receptor agonists on Ca2+ influx into 
RGCs, using a purified RGC culture. Glutamate is the major excitatory neurotransmitter in the 
retina mediating the communication between bipolar cells and RGCs. In this experiment, 30 
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µM glutamate plus 10 µM glycine, and a Mg2+-free extracellular solution, was used to 
stimulate Ca2+ influx into cultured RGCs by activating both NMDA and non-NMDA glutamate 
receptors and indirectly VDCCs, as previously described (Hartwick et al., 2004), though in these 
conditions Ca2+ influx was found to be primarily mediated by NMDA glutamate receptors 
(Hartwick et al., 2008). We now present evidence showing an inhibitory effect of NPY on 
glutamate-evoked increase in [Ca2+]i on purified RGCs likely through Y1 receptor activation (Fig. 
3.6). This result suggests that NPY, released from amacrine cells (Oh et al., 2002), may activate 
post-synaptic Y1 receptors on RGCs inhibiting glutamate receptors or VDCC, thus modulating 
the effect of glutamate released from bipolar cells. 
We further explored the modulatory potential of NPY on RGC spiking activity using a 
MEA (Meister et al., 1994). Although application of NPY or NPY receptor agonists did not affect 
the spontaneous spiking activity, a small increase was found at the initial burst response of 
OFF-type RGCs upon Y1/Y5 receptor activation (Fig. 3.9). We hypothesized that modulatory 
effects of NPY receptor activation may be exerted within the circuitry generating centre-
surround organization within the receptive field of OFF-type RGCs at the level of amacrine 
cell-RGCs (Sinclair et al., 2004). A decreased contribution of ON bipolar cell signal to this 
circuitry could be responsible for this effect although that may not be the case since Y2 
receptor activation, but not Y1 or Y5, was reported to inhibit rod bipolar cells (D'Angelo and 
Brecha, 2004). Another possibility is that the modulatory effect may reside at the level of 
horizontal cell circuitry at the OPL, since it contributes to centre-surround organization 
(Wassle and Boycott, 1991), and Y1 receptor was shown to localize in rat horizontal cells 
(D'Angelo et al., 2002). 
In another experiment paradigm, ex vivo retinal preparations were exposed to NMDA 
to induce an excitatory stimulus to RGCs. We chose NMDA instead of glutamate since in intact 
retina even high concentrations of glutamate have no effect on RGC Ca2+ levels (Hartwick et 
al., 2004) due to the presence of glutamate uptake systems (Thoreson and Witkovsky, 1999). 
We confirmed that Y1 receptor activation is able to modulate directly RGC responses by 
attenuating the NMDA-induced increase in RGC spiking activity (Fig. 3.11). These results 
suggest that the activation of Y1 receptors present in RGC dendrites is responsible for the 
modulatory effect observed. Nevertheless, the contribution of Y1 receptor expressing 
amacrine cell inputs onto RGC dendrites may be also important (D'Angelo et al., 2002). 
Additional studies are needed to clarify the cellular contribution (RGC versus amacrine cells) 
and localization of Y1 receptor activation to the alterations in RGC spiking activity, and whether 
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Y1 receptor activation is associated to a particular RGC type or modulates a specific visual task 
(Gollisch and Meister, 2010). 
NPY has been shown to prevent neuronal cell death, also in the retina, induced by 
excitotoxic insults (Silva et al., 2003; Xapelli et al., 2007; Santos-Carvalho et al., 2013b). To 
further address this issue in the retina, we used an in vitro model, cultured retinal explants 
exposed to NMDA, as well as an in vivo model of retinal I-R injury. Both cultured retinal 
explants and the I-R model have been used to evaluate potential neuroprotective strategies 
targeting retinal neurons, specially RGCs (Lagreze et al., 1998; Goodyear and Levin, 2008; Peng 
et al., 2011; Zhang et al., 2012). We found that NPY pre-treatment was able to prevent NMDA-
induced cell death in retinal explants, through the activation of Y1 and Y5 receptors (Fig. 3.13). 
This result confirm previous studies showing neuroprotective effects upon Y1 or Y5 receptor 
activation (Silva et al., 2003; Xapelli et al., 2007; Smialowska et al., 2009), including in retinal 
neurons (Santos-Carvalho et al., 2013b). However, pre-treatment with NPY was not able to 
prevent the decrease in Brn3a-positive RGCs induced by NMDA exposure (Fig. 3.15). This 
result indicates that the neuroprotective effect exerted by NPY pre-treatment found in TUNEL 
and PI assays might be mainly restricted to amacrine cells and does not extend to RGCs. This 
selective effect may be explained by the localization of NPY and NPY receptors in the rat retina. 
In fact, in the GCL, NPY was shown to be localized in displaced amacrine cells but not in RGCs 
(Oh et al., 2002), and Y1 receptor was found to be expressed in amacrine cell dendrites in IPL 
(D'Angelo et al., 2002). Therefore, we hypothesized that the activation of NPY receptors in 
amacrine cells may be responsible for the protective effect observed in this cell type and not 
in RGCs. Moreover, in retinal I-R injury model, pre-treatment with NPY was not able to prevent 
cell death or rescue RGCs (Fig. 3.16). This observation contrasts with the protective effect of 
NPY when injected intravitreally before the intravitreal injection of glutamate, in a model of 
glutamate-induced injury in the retina (Santos-Carvalho et al., 2013b). In fact, retinal I-R injury 
involves a complex cascade of destructive events including excessive glutamatergic 
stimulation and calcium influx, oxidative stress due to energy failure, and inflammatory 
processes, making difficult to determine the treatment strategy (Osborne et al., 2004). 
Therefore, further studies are needed in order to evaluate whether NPY neuroprotective 
effects detected in cultured retinal explants can be translated to animal models of retinal 
degenerative diseases.
  
 
 
 
 
  
 
 
 
 
 
 
CHAPTER 4 
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4.1 – Introduction 
 
 Sildenafil is a PDE type 5 inhibitor widely used for treatment of erectile dysfunction 
(Salonia et al., 2003), and also for pulmonary arterial hypertension (Montani et al., 2013). 
Patients with erectile dysfunction have experienced transient and mild impairments of colour 
discrimination, which are occurring at the peak of the drug action (Laties and Zrenner, 2002). 
Moreover, sildenafil was found to decrease visual performance, particularly temporal 
response, in S-cone isolating conditions (Stockman et al., 2007), and, in rare cases, transient 
blindness was reported (Montastruc et al., 2006). It has also been suggested as a possible, but 
not yet certain, cause of anterior ischaemic optic neuropathy (Carter, 2007). However, other 
studies reported no visual toxic effects in both human patients and laboratory animals even 
after long periods of drug daily use (Vatansever et al., 2003; Cordell et al., 2009; Zoumalan et 
al., 2009). 
Different electrophysiological studies have investigated the effect of the drug on the 
retinal function. In vivo ERG recordings showed decreases in both a- and b-wave amplitudes 
in sildenafil-treated patients (Vobig et al., 1999), or inversely, an increase in the scotopic ERG 
responses, but a decrease in the photopic response (Luu et al., 2001). Other studies reported 
an increase in Naka-Rushton equation Vmax, suggesting higher rod response after sildenafil 
ingestion (Gabrieli et al., 2001; Gabrieli et al., 2003). More consistently, among all human 
studies, sildenafil enlarged the latencies of the different responses (Luu et al., 2001; Jagle et 
al., 2004; Jagle et al., 2005). Ex vivo experiments have also shown some contradictory results. 
Sildenafil has been shown to increase ERG amplitudes in the rat retina (Barabas et al., 2003), 
whereas it decreases ERG amplitudes in bovine and human retinas, while increasing the 
latencies (Luke et al., 2005; Luke et al., 2007). 
These effects of sildenafil on retinal function could be related to the inhibition of PDE5, 
which is expressed in retinal cells, including human RGCs (Foresta et al., 2008). However, apart 
from its effect on PDE5, sildenafil can also inhibit other PDEs including PDE6, which controls 
the phototransduction cascade in photoreceptors (Beavo, 1995; Lamb, 2013). Sildenafil 
appears almost equally potent on cone PDE6 as on PDE5, whereas it seems slightly less potent 
on rod PDE6 (Ballard et al., 1998; Zhang et al., 2005). The functional relevance of blocking 
photoreceptor PDE6s was demonstrated following rat retinal explant incubation with 
zaprinast, another mixed PDE5/6 blocker (Zhang et al., 2005). This blocker induced an 
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elevation of cGMP and the consequent photoreceptor death attributed to an excessive 
activation of the cGMP-gated channels generating the dark current in photoreceptors 
(Vallazza-Deschamps et al., 2005). PDE4s are also expressed in RGCs, bipolar cells, cholinergic 
amacrine cells and rods (Whitaker and Cooper, 2009), whereas PDE1 and PDE9 were described 
so far in bipolar cells (Dhingra et al., 2008). 
Together, the previous studies have reported conflicting results on the effect of 
sildenafil on retinal function. To further understand the effect of different concentrations of 
sildenafil on principal characteristics of light-induced RGC responses (magnitude and latency) 
and the spontaneous firing rate, we have analysed, for the first time, the retinal output signal 
at the RGC level in the presence of sildenafil. 
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4.2 – Results 
 
 
4.2.1 – Sildenafil at high concentration acutely increases RGC spiking activity and abolishes 
light responses 
 
 ON- or OFF-type RGC light responses were recorded on a MEA upon a series of 10 
consecutive stimulus blocks consisting of 5 sec light followed by 10 sec dark (Fig. 4.1). After a 
10 min application of a high concentration of sildenafil (30 µM), we found a rapid, partial or 
complete, abolishment of RGC light responses in both ON- and OFF-types (Fig. 4.2 and 4.3, 
respectively). This result confirms that sildenafil can affect retinal function acutely inhibiting 
the retinal output. However, we noticed that among the 10 consecutive stimulus blocks, the 
responses of ON-type RGCs to the first block appeared enlarged in both light and dark period 
(Fig. 4.2 B). This atypical ON-response, which was only observed at 30 µM sildenafil (Fig. 4.4), 
was not observed in the following ON responses, which were heavily suppressed (Fig. 4.2 D). 
When considering the spontaneous activity in dark, sildenafil application (0.3 to 30 µM) for 10 
min did not induce statistically significant differences on either ON- or OFF-type RGCs, though 
some cells exhibited a slight increase in spontaneous activity but only at the highest (30 µM) 
concentration (Fig. 4.5). 
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Figure 4.1. Schematic representation of sildenafil application to ex vivo retinas. Sildenafil (0.3 to 
30 µM) was applied for 10 (A) or 60 min (B) under continuous perfusion. After sildenafil application, 
a period of 60 min of washout was performed. Arrows indicate MEA recordings, before sildenafil 
application (Baseline, open arrow), upon sildenafil, or during washout period. 
Figure 4.2. Effects of high concentration of sildenafil on ON-type RGC light responses. Examples 
of RGC light responses before (baseline) and after exposure to 30 µM sildenafil for 10 min. Series 
of 10 consecutive stimulus blocks, each consisting of 5 sec of light period followed by 10 sec dark, 
were delivered to ex vivo retinas. Raw recordings for 5 consecutive stimulus blocks are shown for 
an ON-transient RGC, before (A) and after 30 µM sildenafil application for 10 min (B). Note the 
enlarged response to the first stimulus block. Peri-stimulus time histograms (PSTHs) and raster plots 
for ON-transient RGC responses are shown for five consecutive stimulus blocks before (C) and after 
30 µM sildenafil application for 10 min (D). After 30 µM sildenafil application RGC responses are 
acutely reduced or abolished. Note that raster plots representing spiking events become not 
aligned with light period of stimulus blocks (B). White rectangles indicate duration of light period. 
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Figure 4.3. Effects of high concentration of sildenafil on OFF-type RGC light responses. Series of 
10 consecutive stimulus blocks, each consisting of 5 sec of light period followed by 10 sec dark, 
were delivered to ex vivo retinas. Example of raw recording of an OFF-transient RGC before (A) and 
after application of 30 µM sildenafil for 10 min (B) is shown.  Peri-stimulus time histograms (PSTHs) 
and raster plots of OFF-transient RGC responses are shown for five consecutive stimulus blocks 
before (C) and after application of 30 µM sildenafil for 10 min (D). Note that RGCs responses are 
acutely reduced or abolished after sildenafil application. White rectangles indicate duration of light 
period. 
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Figure 4.4. Quantification of spiking activity for the first stimulus block of ON-type RGC responses 
following application of high concentrations of sildenafil. (A) Raw recordings for the first stimulus 
block for an ON-transient RGC before (baseline) and after exposure to 30 µM sildenafil for 10 min. 
The white rectangle indicates the duration of light period. (B) Quantification of spiking events for 
ON-transient RGCs after sildenafil application (3 to 30 µM), for 10 min. The graph indicates the 
number of spikes during the light period (white bars) and during the dark period (grey bars) of the 
first stimulus block. The spike count values were normalized to the measurements obtained during 
the baseline recordings. Sildenafil application induced an increase in spiking activity especially 
during the dark period of stimulus block. * p<0.05, compared to baseline. Kruskal-Wallis followed 
ďǇ DuŶŶ’s test. 
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Figure 4.5. Maintenance of the RGC spontaneous firing rate after sildenafil application. Effects of 
sildenafil application (0.3 to 30 µM, for 10 min) on the RGC spontaneous spiking activity were 
evaluated. RGCs were divided in ON- (A) and OFF-type (B). Spontaneous spiking rates were 
normalized to the baseline values obtained before exposure to drug. RGCs exhibited a spontaneous 
baseline spiking rate of 4.6 ± 4.1 Hz for ON-type RGCs and 19.3 ± 8.6 Hz for OFF-type RGCs. Only at 
the highest sildenafil concentration (30 µM) some RGCs showed increased spontaneous spiking rate 
after sildenafil application, although no statistically significant difference was found. 
 
4.2.2 – Sildenafil affects the RGC light responses in a concentration-dependent manner 
 
To further elucidate the sildenafil effects on light responses, we applied escalating 
sildenafil concentrations from 1 to 30 µM in order to evaluate its concentration-dependent 
effects. Since the response to the first stimulus block included the response of a non-adapted 
retina where activity from neighbouring RGCs introduced extra noise in individual recording 
electrodes, we always excluded the first stimulus block from the measurements for 
quantification. In ON-type RGCs the application (10 min) of sildenafil induced a concentration-
dependent decrease in light response magnitude (Fig. 4.6). Such effect was observed for both 
initial burst response to light onset (Fig. 4.6 A), and for 1 sec and 5 sec rate (Fig. 4.6 B and C, 
respectively). The highest sildenafil concentration (30 µM) completely suppressed the ON- and 
OFF-type light responses in 50% of RGCs. When light responses were detected for 30 µM, they 
were strongly reduced (Fig. 4.6 A-C). 
After sildenafil application, we perfused retinas with a drug-free Aŵes’ ŵediuŵ for up 
to 60 min to assess the reversibility of sildenafil effects on ON- and OFF-type responses. We 
also recorded the response to 10 consecutive stimulus blocks every 10 min in order to monitor 
the RGC light response during the entire protocol. After 60 min of washout, although partial 
recovery (to 89.8 ± 18.7% for 10 µM and to 60.8 ± 9.4% of initial response for 30 µM) of the 
magnitude may be seen for the initial burst (Fig. 4.6 A), it was hardly found especially for 5 sec 
rate (Fig. 4.6 C), which may indicate residual alterations of retinal response for long periods 
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after cessation of drug exposure. We also quantified the latency of ON-response and found 
that this principal parameter of light responses was greatly increased in a similar 
concentration-dependent fashion as response magnitudes (Fig. 4.6 D). For 10 and 30 µM 
sildenafil concentrations, the increase in latency of ON-responses reached 272.9 ± 55.4 and 
387.4 ± 106.0% of initial response, respectively. However, contrarily to ON-response 
magnitudes, their latencies were clearly recovered, though not completely, after 60 min of 
washout. For 10 µM sildenafil concentration the ON-response latency recover to 143.0 ± 7.4% 
and for 30 µM concentration the recovery reached 197.5 ± 21.6% of initial response (Fig. 4.6 
D). 
 
Figure 4.6. Concentration-dependent and reversible effects of sildenafil on ON-type RGC light 
responses. Sildenafil application (1 to 30 µM) for 10 min concentration-dependently reduces the 
magnitude of ON-type RGC response to light onset. This reduction was found at both initial burst 
(A), and 1 sec (B) and 5 sec rate (C). The response latencies were increased in a similar 
concentration-dependent fashion (D). After 60 min of washout the recovery of response 
magnitudes were hardly seen especially for 5 sec rate (C). On the contrary, for the response 
latencies, a clear washout of sildenafil effect was found (D). All results were normalized to the 
baseline values obtained before drug exposure. *p<0.05, **p<0.01, compared to baseline; #p<0.05, 
compared to sildenafil (10 min). Kruskal-Wallis folloǁed ďǇ DuŶŶ’s test. 
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Figure 4.7. Concentration-dependent and reversible effects of sildenafil on OFF-type RGC light 
responses. Sildenafil application (1 to 30 µM) for 10 min concentration-dependently reduces the 
magnitude of OFF-type RGC response to dark onset. This reduction was found at both initial burst 
(A), and at 1 sec (B) and 5 sec rate (C). The response latencies were also increased in a 
concentration-dependent manner (D). After 60 min of washout, although some partial recovery of 
response magnitude was seen (A), no recovery was found with increasing sildenafil concentrations 
(A-C). Similarly to ON-type RGCs, the response latencies showed a clear washout of sildenafil effect 
(D). All results were normalized to the baseline values obtained before drug exposure. *p<0.05, 
**p<0.01, compared to baseline; #p<0.05, compared to sildenafil 10 min. Kruskal-Wallis followed 
ďǇ DuŶŶ’s test. 
 
Concerning OFF-type RGCs, a similar pattern of concentration-dependent decrease of 
OFF-response magnitudes was found (Fig. 4.7 A-C). This decrease reached 41.8 ± 10.5% and 
18.3 ± 6.7% of the initial response for 10 and 30 µM, respectively, for the initial burst (Fig. 4.7 
A). Also, the 1 sec and 5 sec rate were reduced (Fig. 4.7 B and C). After 60 min of washout, 
although some partial recovery to 70.4 ± 5.7% of response magnitude was seen for RGCs 
exposed to 10 µM sildenafil (Fig. 4.7 A), no recovery was found with higher (30 µM) 
concentration (Fig. 4.7 A-C). The response latencies were also greatly increased in a 
concentration-dependent fashion. This increase reached 311.0 ± 118.5% and 472.9 ± 66.5% of 
initial response for 10 and 30 µM, respectively. Similarly to ON-type RGCs, a partial recovery 
was evident upon 60 min washout (Fig. 4.7 D). Although not complete, the latencies returned 
to 119.3 ± 7.7% and 219.5 ± 35.1% of initial response for 10 and 30 µM, respectively. Together, 
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these results suggest that although light responses in ON- and OFF-type RGCs recover after 
removal of sildenafil, some characteristics of responses, as magnitudes and latencies, may be 
slightly altered for longer periods. 
 
4.2.3 – Potentiation of sildenafil effects with extended exposure 
 
 Since it cannot be discarded the possibility of cases of sildenafil abuse such as the 
combination with illicit drugs (Lowe and Costabile, 2011), resulting in unpredictable 
pharmacokinetics even with therapeutic doses, we attempted to evaluate how longer 
exposures to lower concentrations would further potentiate the sildenafil-elicited 
modifications on RGC light responses. Therefore, the duration of drug application was 
extended to 60 min for concentrations ranging from 0.3 to 3 µM sildenafil, followed by 
washout. The response to 10 consecutive stimulus blocks was recorded every 10 min. In ON-
type RGCs, even concentrations as low as 0.3 and 1 µM generated higher reduction in 
response magnitude, to 83.8 ± 12.3% and 69.6 ± 9.9% of initial response, respectively, for 
initial burst to light onset (Fig. 4.8 A). The sildenafil effect was enhanced with extended 
exposure for both 1 sec and 5 sec rate (Fig. 4.8 B and C). Note that 60 min of sildenafil washout 
was not sufficient to recover the initial response magnitude (Fig. 4.8 A-C), suggesting thereby 
a massive impregnation of the tissue thus requiring longer recovery periods. For response 
latencies of ON-type RGCs, the same pattern as response magnitudes was found, increased 
effect of sildenafil in latencies with extended exposure and more difficult recovery upon 
washout (Fig. 4.8 D). 
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Figure 4.8. Effects of extended exposures to low concentrations of sildenafil on ON-type RGC light 
responses. Sildenafil application (0.3 and 3 µM) for 60 min induced a reduction of RGC responses 
to light onset more prominent than 10 min application (A). For initial burst (A), 1 sec (B) and 5 sec 
rate (C), the reduction of RGC responses were higher compared to sildenafil for 10 min. Also, the 
reversibility of sildenafil effect upon 60 min of washout was more difficult following 60 min of drug 
exposure (A-C). For the lowest concentration (0.3 µM), washout periods were not recorded. The 
response latencies concentration-dependently exhibited increased values after 60 min of sildenafil 
application (D), and although for 1 µM sildenafil there was a small but statistically significant 
recovery within 60 min of washout, the same was not observed for 3 µM sildenafil. All results were 
normalized to the baseline values before drug exposure. *p<0.05, **p<0.01, ***p<0.001, compared 
to baseline; #p<0.05, compared to sildenafil 60 min. Kruskal-Wallis folloǁed ďǇ DuŶŶ’s test. 
 
 Concerning OFF-type RGCs, extended exposure (60 min) to sildenafil also potentiated 
the effects on response magnitudes (Fig. 4.9 A-C). For the lowest (0.3 µM) concentration used, 
the initial burst response was not affected even after 60 min of drug application, suggesting 
higher resilience of OFF-type RGCs compared to ON-type RGCs for this lowest concentration. 
Nevertheless, 5 sec rate (Fig. 4.9 C), but not 1 sec rate (Fig. 4.9 B), was reduced to 68.2 ± 10.7% 
of initial response after 60 min of 0.3 µM sildenafil application. This may be explained by 
natural decreased spiking activity observed during recording sessions. Nevertheless, we 
highlight that the initial burst to dark onset was preserved and more reliably indicates whether 
an OFF response is present. For concentrations of 1 and 3 µM sildenafil, for 60 min, we found 
a reduction to 59.6 ± 2.7% and 33.4 ± 1.7% for the initial burst, respectively (Fig. 4.9 A), and 1 
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sec and 5 sec rate (Fig. 4.9 B, C) presented similar behaviour. Although for 1 µM sildenafil 
concentration a small but statistically significant recovery could be found for initial burst 
within 60 min of washout (Fig. 4.9 A), the same was not clear for 3 µM sildenafil concentration. 
In addition, no recovery was observed at 1 sec and 5 sec rate for both 1 and 3 µM. In the case 
of response latencies of OFF-type RGCs, we found increased values after extended sildenafil 
exposure to 60 min. This increase reached 157.0 ± 5.1% and 312.7 ± 12.8% for 1 and 3 µM, 
respectively, after 60 min of sildenafil exposure (Fig. 4.9 A). A clear recovery of latencies was 
observed within 60 min of washout. For 1 and 3 µM sildenafil, latencies returned to 120.8 ± 
5.4% and 143.2 ± 5.9% of initial response (Fig. 4.9 D). It must be noted that in ON-type RGCs 
the recovery from sildenafil effect was not so evident, especially after 60 min of 3 µM sildenafil 
application (Fig. 4.8 D). 
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Figure 4.9. Effects of extended exposures to low concentrations of sildenafil on OFF-type RGC 
light responses. Sildenafil application (0.3 and 3 µM) for 60 min induced a reduction of RGC 
responses to dark onset more prominent comparing to 10 min application, at the level of initial 
burst (A), and at 1 sec (B) and 5 sec rate (C). Recovery from sildenafil effect upon 60 min of washout 
was seen for the initial burst (A), but no recovery was found for 1 sec (B) and 5 sec rate (C). For the 
lowest concentration (0.3 µM), washout periods were not recorded. The response latencies 
concentration dependently exhibited increased values after 60 min of sildenafil (D). However, a 
clear recovery of response latencies was found upon 60 min washout. All results were normalized 
to the baseline values before drug exposure. *p<0.05, **p<0.01, ***p<0.001, compared to 
baseline; #p<0.05, compared to sildenafil 60 min. Kruskal-Wallis folloǁed ďǇ DuŶŶ’s test. 
 
Finally, we also evaluated the effect of extended sildenafil (1 and 3 µM) exposure on 
RGC spontaneous activity. Although we could not assess a genuine dark adapted spontaneous 
activity since retinal preparations were stimulated each every 10 min to monitor RGC light 
responses, we quantified spontaneous spiking rates so a mixed effect of sildenafil and light 
stimulation could be evaluated. For both ON- and OFF-type, RGCs exhibited a small decrease 
upon 60 min of exposure to 1 µM sildenafil, though no dose-dependent effect was observed 
(Fig. 4.10 A and B). However, spontaneous activity of both ON- and OFF-type RGCs seems to 
be decreased after 60 min of washout although statistically significant difference was found 
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only for OFF-type RGCs (Fig. 4.10 B). This result may reflect a prolonged effect of sildenafil 
potentiated by light stimulation. 
Figure 4.10. Effects of extended exposures to low concentrations of sildenafil on RGC 
spontaneous activity. Effect of sildenafil application (1 and 3 µM, 10 to 60 min) on the RGC 
spontaneous spiking activity was evaluated. RGCs were divided in ON- (A) and OFF-type (B). 
Spontaneous spiking rates, when detected, were normalized to the baseline values obtained before 
drug exposure. For both ON- and OFF-type, RGCs exhibited a small decrease for 1 µM after 60 min 
of sildenafil exposure, though no dose-dependent effect was observed. However, spontaneous 
activity of both ON- and OFF-type RGCs seems to be decreased after 60 min of washout, although 
statistically significant difference was found only for OFF-type RGCs (B). All results were normalized 
to the baseline values before drug exposure. *p<0.05, compared to baseline. Kruskal-Wallis 
folloǁed ďǇ DuŶŶ’s test. 
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4.3 – Discussion 
 
Our results demonstrate that sildenafil has a significant and dose-dependent effect on 
the retina, and in particular, on the RGCs, illustrating the critical changes occurring in RGC light 
response principal characteristics. These changes include a concentration-dependent 
decrease in magnitude and increased latency of light responses, which were partly restored 
during 60 min of washout. Even with low concentrations, which can be measured in human 
plasma (e.g. 1 µM) after sildenafil administration (Kanjanawart et al., 2011), RGC light 
responses showed statistically significant decreases in response magnitudes and increased 
latencies, in particular after prolonged drug exposure (60 min) and repetitive light 
stimulations. The recovery of light responses was incomplete, especially for ON RGCs even 
after prolonged (60 min) washout, which, for other chemicals traditionally applied to the 
retina, takes up to 15 min (Kolomiets et al., 2010). 
 Since the introduction of sildenafil as treatment for erectile dysfunction, reports of 
sildenafil-induced visual alterations have emerged (Laties and Zrenner, 2002). Non-arthritic 
ischemic optic neuropathy has been also reported in patients after sildenafil use, though a 
direct cause-effect has been difficult to demonstrate (Carter, 2007; Azzouni and Abu samra, 
2011). Possible drug-induced modifications of retinal ganglion cell activity could contribute to 
an optic neuropathy. Thus, the reported transient episode of blindness could result from the 
complete disappearance of some ON- and OFF-type RGC light responses as observed after 
high (30 µM) sildenafil concentration (Fig. 4.2 and 4.3). Moderate impairments as in colour 
discrimination have also been reported in human volunteers after sildenafil administration. 
These latter transient alterations appeared to correlate with the peak of sildenafil plasma 
concentration and were fully reversible (Laties and Zrenner, 2002). In a trial assessing ocular 
safety of sildenafil use for pulmonary arterial hypertension, transient adverse events, such as 
chromatopsia, photophobia, and visual brightness were reported with the highest dose of 80 
mg sildenafil three times daily for twelve weeks, though no permanent detrimental effect on 
visual function was found after such a chronic dosage of sildenafil (Wirostko et al., 2012). The 
above mentioned transient visual symptoms could result from the decreased or delayed RGC 
light responses, as we found in this study. Particularly, the RGC response latencies are known 
to be a key component in the transmission of spatial structure of images to visual brain centres 
(Gollisch and Meister, 2008). 
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 Regarding acute sildenafil effects, studies in human and laboratory animals have yield 
contradictory results. Both increased and decreased light responses have been reported after 
sildenafil administration, especially in ERG measurements. Such apparently inconsistent 
results could be attributed to the atypical increase in light response magnitude followed by a 
decrease. For example, Barabas and colleagues found increased ERG amplitude with 1 µM 
sildenafil in rat retina (Barabas et al., 2003), while other authors, using bovine retinas, 
reported decreased a-wave and b-wave amplitudes with sildenafil concentrations as low as 
0.3 µM and 0.1 µM, respectively (Luke et al., 2005). Moreover, acute ERG changes, in scotopic 
range, have been recorded as increased b-wave amplitudes and higher rod light sensitivity 
after 50 mg sildenafil ingestion in human volunteers (Gabrieli et al., 2003). Other studies found 
decreased visual sensitivity after 100 mg sildenafil (Stockman et al., 2007). Some of these 
studies have focused only on one sildenafil dose, but different doses and light stimulation 
paradigms were applied across these different studies such that results are difficult to 
compare. In the present study, we intended to evaluate the effects of sildenafil application, 
particularly onto RGC light responses, which was never addressed before, using various drug 
concentrations including low concentrations found in human plasma after sildenafil 
administration (1 µM) (Kanjanawart et al., 2011). In our experiments, the light responses were 
modified even at the lowest concentrations used (0.3 and 1 µM), whereas the RGC 
spontaneous activity did not display a statistically significant difference even upon application 
of the highest drug concentration (Fig. 4.5). 
The attenuation of RGC light responses and extended time to peak/latency found in 
the present study (Fig. 4.6-4.9) are in accordance with previous reports showing decreased 
ERG amplitudes and increased implicit time in bovine and human retinas (Luke et al., 2005; 
Luke et al., 2007). Interestingly, we showed that extended exposure at lower concentrations 
together with the repetitive light stimulation potentiated the effectiveness of sildenafil-
induced attenuation of light response (Fig. 4.8 and 4.9). In particular, the ON-type responses 
did not recover even after extended periods of washout (Fig. 4.9). The concentration of 1 µM 
is easily found in human plasma after sildenafil use (Kanjanawart et al., 2011). Moreover, it is 
possible that some patients take doses above the recommended therapeutic dose, reaching 
peak plasma concentration above 1 µM, particularly patients suffering from liver disease or 
renal dysfunction. At concentrations of 1 µM and 3 µM, although we did not find strong effects 
on RGC light-responses after 10 min sildenafil exposure, extending the drug exposure to 60 
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min, we found a suppression of the light response magnitude and delayed latencies as seen 
for shorter sildenafil exposure (10 min) with higher concentrations. 
When measuring RGC light responses upon the 30 µM sildenafil application, there was 
an atypical increase in response magnitude in the first stimulus block (Fig. 4.2). However, 
following responses to subsequent stimuli were greatly decreased. This transient sildenafil 
potentiation of the light response could result from the reported increase in photoreceptor 
sensitivity after sildenafil (Barabas et al., 2003; Gabrieli et al., 2003). The partial sildenafil 
inhibition of PDE6 could have increased the photoreceptor cGMP intracellular concentration 
thus enlarging the photoreceptor functional dynamics. However, the maintained PDE6 
inhibition would lead to a progressive increase in photoreceptor cGMP and a consequent 
constant photoreceptor depolarization (Zhang et al., 2005; Simon et al., 2006). Such an 
excessive activation of cGMP-gated channels may generate risks for the cell viability as we 
previously reported on retinal explants (Vallazza-Deschamps et al., 2005). This transient 
potentiation of the RGC light responses would be consistent with enhanced PDE6 inhibition 
by sildenafil upon light stimulation. 
 In summary, we found that sildenafil concentration-dependently attenuates RGC light 
responses in terms of magnitude and latencies. Moreover, these effects are potentiated by 
extended drug exposure and repeated light stimulation. To our knowledge, this is the first 
time the effects of sildenafil directly on RGC spiking activity are evaluated. The present study 
highlights the acute effects of sildenafil on RGC light responses, which are transmitted towards 
brain visual centres. These results on transient losses of light responses or, at least, magnitude 
decreases warn against sildenafil abuses, which could lead to more severe and irreversible 
long-term visual losses (Lowe and Costabile, 2011). Since sildenafil and its first metabolite UK-
103,320 were identified in human post-mortem vitreous humour, suggesting that the drug 
can reach the retina directly (Lewis et al., 2006), understanding the acute visual alterations is 
needed, especially under repeated administration. 
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In this study, we present evidence supporting the localization of NPY and NPY 
receptors in the inner retina and indicating a role for NPY system in modulation of retinal 
circuitry. The presence of mRNA for both NPY and NPY receptors (Y1, Y2, Y4, and Y5) detected 
in purified RGCs extends the findings of previous works (D'Angelo and Brecha, 2004; Alvaro et 
al., 2007). Regarding the immunoreactivity of NPY and NPY receptors in the rat retina, we 
confirmed that NPY is localized in cell bodies of amacrine cells in INL and displaced amacrine 
cells in GCL, which the processed extend and ramify in IPL (Oh et al., 2002). We extended the 
study of Y1 and Y2 receptor localization (Canto Soler et al., 2002; D'Angelo et al., 2002; Santos-
Carvalho et al., 2013a), showing that Y1-ir is localized to GCL and Y2-ir is found in stratum 1 of 
IPL and in cell bodies of proximal INL. We also present novel evidence indicating the 
localization of Y4 receptor in cell bodies of GCL, and proximal and distal INL. Concerning Y5 
receptor, immunoreactivity was detected for the first time in Müller cells. In addition to 
immunofluorescence data, we present further evidence showing the presence of functional 
active NPY receptors in the inner retina using [35S]GTPγS binding assay. 
We presented evidence showing an inhibitory effect of NPY on glutamate-evoked 
increase in [Ca2+]i on purified RGCs likely through Y1 receptor activation suggesting that NPY, 
released from amacrine cells (Oh et al., 2002), may activate post-synaptic Y1 receptors on 
RGCs. In addition, we found that Y1/Y5 receptor activation induces a small increase in the initial 
burst response of OFF-type RGCs. This result indicates that NPY might exert modulatory 
effects within the circuitry generating centre-surround organization in the receptive field of 
RGCs, which extends previous findings in this issue by Sinclair and colleagues (Sinclair et al., 
2004). Indeed, we found that Y1 receptor activation is able to modulate directly RGC responses 
by attenuating the NMDA-induced increase in RGC spiking activity. Clearly, more studies are 
needed to clarify whether the activation of Y1 receptors is associated to a particular RGC type 
or modulates a specific visual task (Gollisch and Meister, 2010). 
We presented evidence supporting that NPY exerts neuroprotective effects, upon Y1 
or Y5 receptor activation, in cultured retinal explants, confirming previous studies (Silva et al., 
2003; Xapelli et al., 2007; Smialowska et al., 2009; Santos-Carvalho et al., 2013b). However, 
pre-treatment with NPY was not able to prevent the decrease in Brn3a-positive RGCs induced 
by NMDA exposure to cultured retinal explants or induced by retinal I-R injury. Therefore, 
further studies are needed in order to evaluate whether NPY neuroprotective effects detected 
in cultured retinal explants can be translated to animal models of retinal degenerative 
diseases. 
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In the second part of this work, we took advantage of MEA technique in ex vivo retinal 
preparations as an easy method to evaluate the acute effects of exogenously applied drugs 
on RGC activity. We found that sildenafil concentration-dependently attenuates RGC light 
responses. Even with low concentrations, which can be measured in human plasma (e.g. 1 
µM) after sildenafil administration (Kanjanawart et al., 2011), RGC light responses showed 
decreased response magnitudes and increased latencies, in particular after prolonged drug 
exposure (60 min) and repetitive light stimulations. These results extend previous findings 
showing decreased ERG amplitudes and increased implicit time in bovine and human retinas 
(Luke et al., 2005; Luke et al., 2007). In addition, high sildenafil concentration (30 µM) induced 
an atypical increase in response magnitude in the first stimulus block, but not in subsequent 
stimuli which were greatly decreased. This transient sildenafil potentiation of the light 
response might result from the reported increase in photoreceptor sensitivity after sildenafil 
(Barabas et al., 2003; Gabrieli et al., 2003) which may be explained by increased photoreceptor 
cGMP intracellular concentration due to partial inhibition of PDE6 by sildenafil. Altogether, 
these findings contributes to the understanding of the acute visual alterations reported in 
patients using sildenafil. 
Thus, we show that MEA recordings in ex vivo retinas might be a valuable method to 
understand how RGC circuitry, as the output signal from the retina to the brain, is affected by 
different drug treatments. This understanding is an important step towards the development 
of neuroprotective strategies aimed to halt RGC death, and needed for retinal degenerative 
diseases such as glaucoma. 
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